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ABSTRACT 
 Pneumonia and sepsis are distinct but linked public health concerns. Each 
condition is the leading cause of the other; however, the responses controlling the 
susceptibility between the two disease processes remain speculative. The acute phase 
response (APR) is an important component of the host immune response during 
pneumonia and sepsis, and primarily driven by the activation of hepatocyte transcription 
factors NF-κB RelA and STAT3.  
 While the NF-κB pathway is essential for inflammation and hepatocyte function, 
its inactivation has been associated with hepatotoxicity. Liver injury is an independent 
risk factor for sepsis morbidity and mortality, suggesting that pathways promoting liver 
homeostasis may limit the systemic consequences of pneumonia. To identify conditions 
in which NF-κB RelA is required for liver resilience, we challenged mice lacking 
hepatocyte RelA (hepRelAΔ/Δ) and wildtype (WT) controls with E. coli, K. pneumoniae, 
S. pneumoniae, LPS, or αGalCer to induce pneumonia, sepsis, and/or NKT cell 
activation. Severe hepatotoxicity was observed in hepRelAΔ/Δ mice in all conditions 
examined in association with apoptosis, which could be prevented by neutralization of 
TNFα. Lastly, these changes were associated with remodeling of the hepatic 
transcriptome, likely reflecting both the cause and consequence of hepatoxicity.  
  ix
 We have previously shown that activation of STAT3 in hepatocytes limits 
pneumonia susceptibility during endotoxemia, but the mechanisms whereby this liver 
APR provides protection are unknown. Iron sequestration is a defense mechanism against 
bacterial infections, which require iron for growth. Based on previous observations that 
alveolar lining fluid is favorable for bacteria in the absence of liver STAT3, we 
investigated whether liver APR limits pneumonia susceptibility during sepsis by 
withholding iron to prevent bacterial outgrowth. WT mice or mice lacking hepatocyte 
STAT3 (hepSTAT3Δ/Δ) mice were challenged with endotoxemia followed by E. coli 
pneumonia, or cecal ligation and puncture (CLP). Induction of mRNA encoding several 
essential iron-regulating factors was ablated in hepSTAT3Δ/Δ mice after endotoxemia and 
pneumonia, and post CLP. Additionally, liver STAT3 activation significantly remodeled 
the pulmonary transcriptome during endotoxemia, which potentially represents other 
protective mechanisms.  
 Taken together, these results suggest that hepatic APR is an important 
immunological interface modulating pneumonia and sepsis interaction and susceptibility. 
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CHAPTER ONE: INTRODUCTION 
 
Pneumonia 
Significance and Epidemiology 
 Pneumonic infections have been recognized throughout human history as a 
prevalent and severe disease entity, with descriptions of symptoms dating back to ancient 
civilizations (Abdelnaby, El Deeb et al. 2017). Even Hippocrates (4th-3rd century BC), 
who bestowed the name “pneumonia” to the most serious infections of the lungs, 
described the condition as a disease previously “named by the ancients” (Gattarello and 
Rello 2017). The recognition of microorganisms as causative agents of lung infections 
occurred roughly 150 years ago. Yet, pneumonia continued to cause widespread death 
and disability into the late 1800s and early 1900s. William Osler, the father of modern 
medicine, described pneumonia as “the most fatal of all acute diseases… the ‘Captain of 
Men of Death’”, as pneumonia was the leading cause of death due to infectious disease 
and the third leading cause of death overall (Osler 1898).  
 Several advancements in medicine and public health interventions in the 1900s 
were vital in improving pneumonia mortality. The use of antiserum therapy (Robertson 
and Sia 1924), followed by the discovery of penicillin and other antibiotic therapies 
drastically reduced mortality by nearly 30%  in developed countries (Podolsky 2005). 
Improvements in modern surgery techniques and intensive care, as well as development 
of vaccines against bacterial Haemophilus influenzae in 1988 and Streptococcus 
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pneumoniae in 1977 and 2000 further improved pneumonia outcomes (Blasi, Aliberti et 
al. 2007).  
 However, pneumonia still remains fairly prevalent, even in developed countries. It 
is responsible for a significant portion of mortality and morbidity worldwide as measured 
by disability-adjusted life years (DALYs) lost (Mizgerd 2012). Despite the advancements 
of modern medicine, pneumonia mortality rates have remained relatively stable in the last 
several decades: approximately 40 deaths per 100,000 persons per year (Armstrong, 
Conn et al. 1999). Presently, pneumonia is the third leading cause of hospitalizations, the 
eighth leading cause of mortality (the leading cause of mortality from infection), and the 
leading cause of sepsis (a tightly linked complication discussed below) (Rider and Frazee 
2018). Lung infections affect persons across the socioeconomic and health spectrum; 
however, incidence and need for hospitalization is higher at extreme age distributions. 
The hospitalization rate of children under two years of age is approximately 1,000 
hospitalizations per 100,000 persons per year, while rates for elderly adults age 85 or 
greater is over 4,000 hospitalizations per 100,000 persons per year (Griffin, Zhu et al. 
2013). Outcomes for hospitalized patients are also poor, with 30-day mortality at 10-
12%, readmission rate at 18% (Musher and Thorner 2014). 
 
Causes and Classifications of Pneumonia 
 Pneumonia is not a single disease but a group of syndromes caused by a 
heterogeneous group of microorganisms that includes bacteria, virus, and less frequently 
fungi, and parasites infecting the lung parenchyma (Musher and Thorner 2014). 
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However, a single cause of pneumonia is identified in less than 10% of emergency 
patients (Bartlett 2011). When pneumonia-causing organisms are identified, they are 
numerous and varied by geographic and time setting, vaccine trends, and specific patient 
subpopulations (DeAntonio, Yarzabal et al. 2016, Wuerth, Bonnewell et al. 2016). A 
common classification of pneumonia etiology is based on the setting in which the patient 
acquired the infection. Community-acquired pneumonia (CAP) is any pneumonia that 
was acquired outside of a hospital, in a community setting (Mandell, Wunderink et al. 
2007). A patient who acquired pneumonia 48 hours after being admitted in an inpatient 
setting, such as a hospital, is classified as having hospital-acquired pneumonia (HAP) 
(Kalil, Metersky et al. 2016). Further, any pneumonia acquired 48 hours after 
endotracheal intubation is classified as ventilator-associated pneumonia (VAP) (Kalil, 
Metersky et al. 2016).  
 While there is a spectrum and combination of microorganisms, the majority of 
those detected were viruses (Jain, Self et al. 2015). The most common viruses were 
rhinovirus, influenza viruses, and respiratory syncytial virus (RSV) (Jain, Self et al. 
2015). Although viruses are implicated in pneumonia, the direct cause is often 
complicated by secondary bacterial infections (Hendaus, Jomha et al. 2015). The most 
common bacterial pathogen and third most common causative pathogen in CAP detected 
was Streptococcus pneumoniae, followed by Mycoplasma pneumoniae and 
Staphylococcus aureus (Jain, Self et al. 2015). Other typical bacteria detected in CAP 
include Klebsiella pneumoniae, Haemophilus influenza, Psudomonas aeruginosa, and 
other aerobic and anaerobic gram-negative bacteria (Musher and Thorner 2014, Jain, Self 
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et al. 2015). Although the study by Jain et al. were empowered to identify causative 
agents, organisms were not detected in an astounding 62% of patients tested, and further, 
no single individual organism caused more than approximately 8% of total adult cases. 
Thus, the diverse etiology emphasizes the importance of understanding the underlying 
host biology controlling disease susceptibility. Fungal pathogens are implicated in 
immunocompromised patients with HIV, organ transplants, among others and is also 
commonly associated with HAP (Hage, Knox et al. 2012). Etiology of HAP in non-
ventilated and ventilated patients have many overlaps. Gram-negative bacilli 
(Escherichia coli, Psudomonas aerugenoisa, Acinetobacter, and Enterobacter) and 
Gram-positive cocci (Staphlococcus aureus) are prevalent (Calik, Ari et al. 2018). HAP 
and VAP patients are of particular risk to a growing prevalence of multidrug-resistant 
(MDR) bacterial strains (Rider and Frazee 2018). While penicillin was sufficient 
treatment for Streptococcus pneumoniae, penicillin-resistant strains have risen from 18% 
in 1991 to 35% in 2002 (Doern 2005). Other resistant pneumonia causing strains include 
macrolide-resistant pneumococcus, carbapenem-resistant Klebsiella pneumoniae, and 
methicillin-resistant Staphylococcus aureus (MRSA) (Rider and Frazee 2018).  
 
Clinical Presentation and Pathology 
 Pneumonia is clinically described as an infection of the lower respiratory tract and 
alveoli (Mackenzie 2016). The respiratory tract is not sterile and is constantly exposed to 
commensal and environmental microorganisms (Wu and Segal 2018). Pneumonia occurs 
when intricate balance between pathogens and host defense is disturbed, leading to 
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invasion and propagation in lower airways and alveoli (Mizgerd 2017). There are a 
number of host defenses that work to prevent the proliferation of microorganisms, 
including the host innate immune response composed of immune cells. Sentient cells, 
such as alveolar macrophages and epithelial cells, work to recognize pathogen associated 
molecular patterns (PAMPs) through various receptors to phagocytose and kill 
proliferating bacteria (Quinton, Walkey et al. 2018). However, when the bacteria 
overcome the capacity of the host defenses and proliferate, alveolar macrophages initiate 
the inflammatory response through production of early cytokines such as TNFα, IL-1 and 
IL-6 (Mizgerd 2017, Quinton, Walkey et al. 2018).  
 The inflammatory response, though an essential component of the host defense 
against microorganisms, is also responsible for the clinical and pathological findings 
observed during the course of pneumonia (van der Poll and Opal 2009). Local 
inflammatory cytokines and factors recruit additional immune cells (i.e. neutrophils and 
lymphocytes), humoral defenses, and initiate systemic inflammatory responses (Quinton, 
Walkey et al. 2018). The alveolar capillaries become leaky at the site of inflammation to 
allow extravasation of these immune defenses (Quinton, Walkey et al. 2018). However, 
killing of pathogens by reactive oxygen species and enzymes produced by neutrophils 
also results in acute lung injury (Brinkmann, Reichard et al. 2004, Quinton, Walkey et al. 
2018). The alveolar epithelium becomes damaged and the alveolar space becomes filled 
with proteinaceous and purulent exudate (Ware, Neyrinck et al. 2012). Exudative 
congestion leads to decreased lung compliance, shortness of breath, and worsening 
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hypoxemia, all of which are important clinical signs of severe pneumonia (Brar and 
Niederman 2011).  
 Pneumonia is diagnosed through history and physical examination of respiratory 
infection symptoms, pulse oximetry, and lung sounds. Chest radiographic evaluations are 
a central method to diagnose pneumonia (Watkins and Lemonovich 2011). When 
alveolar infiltrates are seen in the pulmonary spaces of chest radiographs, laboratory 
evaluations are conducted to identify the causative agent and course of treatment 
(Watkins and Lemonovich 2011).  
 
Treatment, Prognosis, and Prevention 
 Once pneumonia diagnosis is made, patients are administered treatment as soon as 
possible (Watkins and Lemonovich 2011, Kalil, Metersky et al. 2016). Antibiotic and 
antiviral therapies are commonly used, but the specific course of treatment varies by 
severity, presence of complications, patient risk factors, and causative agents. Some risk 
factors include young and old age, presence of comorbidities and chronic diseases, 
immunocompromised states, behavioral factors such as smoking and alcohol 
consumption, compliance with immunization and therapy, and the likelihood of 
developing antibiotic-resistant infection (Niederman, Mandell et al. 2001).  
 Recommended antibiotics include fluoroquinolones, β-lactams, macrolides, and 
doxycycline (Waterer, Rello et al. 2011). For CAP, the antibiotic regime is typically five 
to seven days of treatment, except for infections with S. aureus and those complicated 
with bacteremia (Li, Winston et al. 2007, Liu, Bayer et al. 2011). In severe cases of 
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pneumonia, such as when patients progress to acute respiratory distress syndrome 
(ARDS), supportive care and ventilation become necessary (Matthay, Ware et al. 2012). 
HAP often leads to use of broad-spectrum antibiotics due to multi-drug resistant 
organisms and patient risk factors, and generally covers S. aureus, P. aeruginosa, and 
Gram-negative bacilli (Madaras-Kelly, Remington et al. 2012).  
 Many previously healthy adults typically resolve pneumonia after initiating 
antibiotic therapy. However, complications can arise from pneumonia leading to 
respiratory failure, sepsis, metastatic infections, empyema, lung abscesses, multi-organ 
failure, coagulopathy, exacerbations of comorbidities, and complicated pleural effusion 
(Mbata, Chukwuka et al. 2013, Sattar and Sharma 2018). Additionally, patients 
hospitalized with pneumonia suffer from many long-term effects. These patients are at 
increased risk of developing chronic respiratory diseases and recurrent infections. 
Mortality rates are 2.5 times higher 1 year after hospital discharge as compared to 
hospitalized patients who did not have pneumonia (Kaplan, Clermont et al. 2003, 
Waterer, Kessler et al. 2004). Other long-term consequences associated with pneumonia 
hospitalizations include cognitive decline, depression, cardiovascular, cerebrovascular, 
physical limits, and decreased lifespan (Davydow, Hough et al. 2013, Grijalva 2015). 
 The most important measure to reduce the risk of pneumonia is the cessation of 
smoking, which interferes with the immune system and lung function (Almirall, 
Gonzalez et al. 1999). Immunization is also an important preventative measure, 
particularly for patients with existing pulmonary diseases. Two pneumococcal vaccines 
are commercially available: the pneumocoocal polysaccharide vaccine (PPSV23) which 
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is comprised of purified polysaccharides of 23 different serotypes, and the pneumococcal 
conjugate vaccines (PCV7, PCV13) which are comprised of polysaccharides from 
serotype 7 or 13 conjugated with a highly immunogenic diphtheria toxoid protein (Pisano 
and Cifu 2015). However, the PPSV23 does not illicit a strong immunological memory, 
and is not recommended for children under two years of age (Pletz, Maus et al. 2008, 
Pisano and Cifu 2015). The PCV vaccines have been shown to reduce pneumonia 
hospitalizations in children and elderly adults (Assaad, El-Masri et al. 2012, Izu, 
Solomon et al. 2017). Haemophilus influenza type b and influenza vaccines are the only 
other known vaccines that currently exist for other etiologies of pneumonia (Rider and 
Frazee 2018). Despite the availability of these vaccines, morbidity and mortality of 
pneumonia worldwide remains significant.  
 
Sepsis 
Clinical Definition and Significance 
 The first documentation of sepsis occurred in 1600 BC; however, the term 
“sepsis” came from ancient Greek meaning “decay of organic matter” and was referenced 
in the Hippocratic corpus (4th century BC) (Kempker and Martin 2016). However, it was 
not clinically defined until the late 20th century when the discovery of antimicrobials and 
improvements in supportive care allowed physicians to study it in surviving patients. The 
earliest modern definition of sepsis occurred in 1989, when Roger Bone and colleagues 
introduced “sepsis syndrome” which laid the foundation for systemic inflammatory 
response (SIRS) criteria (Bone, Fisher et al. 1989). SIRS was defined as a complex 
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immune response to infection or injury, which include changes in respiratory rate, heart 
rate, temperature, and white blood count (Bone, Balk et al. 1992). The 1991 International 
Consensus Conference formed the first official definition of sepsis (1992). Sepsis was 
defined as SIRS with a suspected or proven infection, and severe sepsis described septic 
patients with organ dysfunction. Septic shock was described as a severe state with an 
acute circulatory failure characterized by persistent arterial hypotension. The definition 
was lightly revised in 2001 when it was acknowledged that SIRS was not specific to 
sepsis and therefore was redefined as the “signs and symptoms of sepsis”, which included 
other clinical symptoms such as altered mental status and hyperglycemia (Levy, Fink et 
al. 2003). In 2016, the definition of sepsis was updated as a life threatening organ 
dysfunction caused by a dysregulated host response to infection, while septic shock 
referred to patients with circulatory and cellular or metabolic abnormalities, identified by 
the requirement of vasopressors (Singer, Deutschman et al. 2016).  
 The true incidence rate of sepsis is unknown and is complicated by the changing 
definition of sepsis, the reporting system, heterogeneity of infecting organisms, and 
geographical diversity (Kempker and Martin 2016). Most incidence reports are from 
high-income countries, such as the U.S. While the results vary, the average incidence of 
sepsis is estimated to range from 300 to 1,031 per 100,000 persons (Gaieski, Edwards et 
al. 2013). An annual 2.8 million deaths are attributed to sepsis (Adhikari, Fowler et al. 
2010), which accounts for approximately a third to half of in-hospital deaths in the U.S 
(Liu, Escobar et al. 2014). While in-hospital mortality has decreased from 28% to 18% 
(Martin, Mannino et al. 2003), the incidence of sepsis has elevated over the past 40 years, 
  
10
with an average annual increase of 13% (Gaieski, Edwards et al. 2013). However, data 
from low-income countries are scarce and are often extrapolated from respiratory tract 
infection trends, with 90% of chest infection deaths thought to be due to sepsis (Kempker 
and Martin 2016).  
 
Causes of Sepsis 
 Sepsis can originate from any infecting organism, and the primary site of 
infection also varies among septic patients. However, sepsis is most frequently caused by 
lung infections, with approximately 40 to 60% of septic patients having causative 
respiratory infections (Karlsson, Varpula et al. 2007, Vincent, Rello et al. 2009). Other 
common sites of infection that leads to sepsis is the abdomen (20%), blood (15%), and 
renal and genitourinary (14%) (Karlsson, Varpula et al. 2007, Vincent, Rello et al. 2009). 
Bacterial infections are commonly associated with sepsis, although data are limited by 
the ability to grow and identify organisms. Gram-negative bacteria, such as Pseudomonas 
(62%) and E. coli (16%), are most commonly detected in those with positive 
microbiological cultures (Gotts and Matthay 2016). Gram-positive bacteria are detected 
in 47% of which S. aureus alone accounts for 20%, and fungal species are detected in 
19% (Gotts and Matthay 2016). Sepsis mortality is especially high in patients with certain 
drug-resistant organisms such as MRSA, Klebsiella, Pseudomonas, and Acinteobacter 
(Hanberger, Walther et al. 2011, Gotts and Matthay 2016).  
 Risk factors for the development of sepsis is associated with a patient’s 
predisposition to infection. These include young and elderly patients, immunosuppressive 
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states, and comorbidities, which are reflective of risk factors for the development of 
pneumonia (Brun-Buisson, Doyon et al. 1995, Angus, Linde-Zwirble et al. 2001, Banta, 
Joshi et al. 2012). However, factors linked to progression of pneumonia to sepsis and 
organ dysfunction are less characterized. 
 
Clinical Presentation & Pathology 
 The clinical presentation of sepsis depends on the site of infection and type of 
pathogen. Typically, sepsis progresses from a local infection to mild systemic 
inflammation and organ dysfunction, to septic shock when the cardiovascular system 
undergoes major alterations (Gotts and Matthay 2016). A patient’s state of organ function 
or rate of failure is determined by the sequential organ failure assessment score (SOFA 
score), which includes respiratory, cardiovascular, hepatic, coagulation, renal, and 
neurological assessments (Singer, Deutschman et al. 2016). Organ dysfunction 
perpetuates and self-reinforces injury during sepsis. For example, endothelial and 
epithelial changes during sepsis are associated with barrier functions of other organs. In 
response to injury or inflammatory signals, the endothelium alters leukocyte adhesion and 
trafficking, coagulant state, vasodilation, and barrier functions (Deutschman and Tracey 
2014). More permeable endothelial and epithelial capillaries in the lung lead to edema 
and hypoxia. When mechanical ventilation becomes necessary for proper lung function, it 
can lead to further injury and enhanced inflammatory responses (Zampieri and Mazza 
2017). Epithelial barrier loss in the intestines increases gut bacterial translocation (Fink 
2003). Impaired hepatocytes of the liver are unable perform functions such as clearing 
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bilirubin or processing translocated gut bacteria, worsening systemic inflammation 
(Strnad, Tacke et al. 2017).  
 The inflammatory response during sepsis consists of both pro- and anti-
inflammatory states. Proinflammatory responses are initiated by sentient leukocytes (i.e. 
macrophages, monocytes, granulocytes, natural killer cells, and dendritic cells) which 
detect pathogens through PAMPs and injured cells through damage associated molecular 
patterns (DAMPs) (Delano and Ward 2016). PAMPs and DAMPs activate the innate 
immune system through various cell surface and cytosolic receptors that initiate the 
transcription of type 1 interferons and proinflammatory cytokines TNFα, IL-1, and IL-6 
(Schulte, Bernhagen et al. 2013, Delano and Ward 2016). These early inflammatory 
cytokines orchestrate events that rapidly control minor and localized infections (Schulte, 
Bernhagen et al. 2013). However, when the response exceeds a threshold, systemic injury 
can result. Reactive oxygen species (ROS) generated by neutrophils damage cellular 
components and mitochondria, leading to cellular metabolic dysfunction (Victor, 
Espulgues et al. 2009, Leliefeld, Wessels et al. 2016). Complement activation increases 
ROS and enzyme release by granulocytes and increases endothelial permeability (Ward 
and Gao 2009). Aberrant activation of coagulation, fibrin deposition, and tissue factor 
can result in disseminated intravascular coagulation that injures the microvasculature and 
organs, activating inflammation (Simmons and Pittet 2015).  
 Compensatory anti-inflammatory response is also activated in early states of 
sepsis. IL-10 is produced by a variety of leukocytes to suppress the production of IL-6 
and stimulate soluble TNFα receptor and IL-1 receptor antagonist (Schulte, Bernhagen et 
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al. 2013). Cells that undergo apoptosis are engulfed by macrophages which release IL-10, 
TGFβ, and bioactive lipids that reduce ROS, endothelial permeability, and leukocyte 
recruitment (Fullerton, O'Brien et al. 2013). Expansion of T regulatory cells (Tregs) also 
plays an important role in producing anti-inflammatory cytokines and clearance of 
cytotoxic cells (Fullerton, O'Brien et al. 2013). However, these anti-inflammatory 
responses contribute to an immune dysfunctional state of immunosuppression, where 
patients become susceptible to secondary infections such as hospital-acquired pneumonia 
(van Vught, Klein Klouwenberg et al. 2016). Several anti-inflammatory cytokines have 
been implicated in immunoparalysis. In particular, high levels of IL-10 stimulated by PD-
1 in response to high TNFα has been associated with impairment of T cell proliferation 
and maintenance of immunoparalysis in patients during sepsis (Said, Dupuy et al. 2010). 
Anergy of immune cells also contributes to sepsis-related immunosuppression. T cells 
demonstrate impaired response to antigen and decreased release of cytokines (Heidecke, 
Hensler et al. 1999). Macrophages and monocytes express less MHCII and co-
stimulatory molecules, and are associated with poorer outcomes in sepsis (Saenz, Izura et 
al. 2001). Other immune functions such as ROS generation, phagocytosis, and 
chemotaxis are also impaired in septic patients (Hotchkiss, Monneret et al. 2013). 
Additionally, autopsy studies of patients who died of sepsis show profound immune cell 
death (Hotchkiss, Monneret et al. 2013). Apoptosis is commonly observed in T cells, B 
cells, natural killer cells, and follicular dendritic cells in septic patients, and lymphopenia 
is associated with secondary infection and mortality (Hotchkiss, Monneret et al. 2013, 
Drewry, Samra et al. 2014). Sepsis reflects the interaction between mechanisms that 
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increase and decrease inflammation, leading to immune dysfunction with deleterious 
consequences.  
 
Relationship to Pneumonia 
 Sepsis and pneumonia are distinct inflammatory diseases in response to infection. 
However, they are integrally linked with each exacerbating the other. Sepsis arises from 
pneumonia more than any other cause (as mentioned above). Conversely, sepsis from 
non-pulmonary infection predisposes patients to pneumonia due, at least in part, to 
sepsis-induced immunosuppression (Bouras, Asehnoune et al. 2018). Ventilator 
associated pneumonia occurs in 10-30% of ventilated septic patients (Chastre and Fagon 
2002). Several studies in rodent models have shown the causative links between pre-
existing sepsis and outcomes of subsequent pneumonia including defective neutrophil 
recruitment, decreased local and systemic cytokine production, and IL-10 in the 
impairment of host defenses (Benjamim, Hogaboam et al. 2003, Deng, Cheng et al. 2006, 
Cao, Xu et al. 2014). However, the mechanisms and signals that prevent pneumonia and 
sepsis from promoting the other are still not well understood.  
 
Management, Prognosis, and Prevention 
 There are no approved molecular therapies for sepsis. The current 
recommendations in the management of sepsis include the early administration of 
appropriate antibiotic treatment to control infections, restoration of tissue perfusion by 
fluid resuscitation, and supportive care (Levy, Dellinger et al. 2010). Vasopressors are 
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recommended, particularly in patients with septic shock (Levy, Dellinger et al. 2010). 
Treatments to normalize gas exchange, glucose control, and oxygen delivery in septic 
patients have been ineffective. Therapies aimed at specific molecular targets during 
sepsis have also been either unsuccessful or harmful. For example, anti-TNFα aimed to 
decreased inflammation increased mortality in septic patients (Fisher, Agosti et al. 1996). 
Use of corticosteroids lacked consensus on efficacy after several trials (Schumer 1976). 
Other targets including other cytokine pathways, bacterial virulence factors, and the 
coagulation cascade have also proven unsuccessful (Fink and Warren 2014).  
 It is unsurprising that a single treatment or therapy has not improved sepsis 
outcomes. Studies attempting to prevent sepsis in animal models using anti-TNFα 
demonstrated that administration before an E. coli challenge could prevent shock and 
organ failure (Tracey, Fong et al. 1987). However, the effect was lost if administered 
several hours after infection, demonstrating the dynamic shifting kinetics of a single 
cytokine. Even beyond the challenges of optimizing drug pharmacokinetics and treatment 
length, sepsis is a complex heterogeneous syndrome. Heterogeneity derives from 
biological variability of the patient population and type of infection (etiology and 
location) (Iskander, Osuchowski et al. 2013). Additionally, sepsis is a complex syndrome 
that affects multiple molecular cascades and organ dysfunction that is self-reinforcing 
and linked to other systems, thus blocking one pathway as a possible treatment may not 
in fact be effective or have unintended consequences.  
 Sepsis and septic shock are associated with high mortality and substantial 
morbidity. Nearly 25-30% of septic patients die during hospitalization (Cohen, Vincent et 
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al. 2015). Early antibiotic treatment and fluid resuscitation has been associated with 
reduced mortality in clinical trials (Pro, Yealy et al. 2014). However, many patients are 
admitted to long-term facilities (Kahn, Benson et al. 2010), and readmissions are frequent 
(Wang, Derhovanessian et al. 2014). Sepsis survivors suffer from long-term morbidity 
including decreased quality of life, cognitive impairment, and functional disability 
(Nesseler, Defontaine et al. 2013).  
 
The Liver During Infection 
The Hepatic Acute Phase Response (APR) 
 The liver plays functional roles in metabolism, storage, detoxification, and 
immunity. The healthy liver is in a constant but regulated state of inflammation due to the 
exposure of pathogens, toxins, malignant cells, and other host factors within the 
circulation (Robinson, Harmon et al. 2016). These PAMPs and DAMPs are detected by 
hepatocytes and a large pool of liver resident immune cells, of which the full spectrum is 
still uncertain (Robinson, Harmon et al. 2016). Kupffer cells, the resident macrophages 
which compromise a third of non-parenchymal cells, produce pro- and anti-inflammatory 
cytokines in response to stimuli (Kojima, Suzuki et al. 2003). Dendritic cells, Myeloid-
derived suppressor cells (MDSCs), innate lymphoid cells (NK and NKT cells), 
lymphocytes, and even parenchymal cells contribute to the hepatic cytokine milieu 
(Robinson, Harmon et al. 2016). Normal metabolic processes and products such as 
succinate, triglycerides, and cholesterol promote TLR signaling and inflammasome 
formation, triggering inflammation (Tannahill, Curtis et al. 2013, Tall and Yvan-Charvet 
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2015). Despite basal levels of inflammation, the liver is mostly immune tolerogenic 
(Robinson, Harmon et al. 2016). However, unchecked or overwhelming inflammation 
drives liver dysfunction and organ injury with systemic consequences. 
 The liver is also extremely responsive to extra-hepatic inflammation. The hepatic 
acute phase response (APR) is an innate immune response to inflammation, infection, and 
injury, which results in changed plasma concentrations of acute phase proteins (APPs) 
(Gruys, Toussaint et al. 2005, Crispe 2016). Hepatocytes alter transcription and 
production of APPs in response to major proinflammatory cytokines TNFα, IL-1, IL-6, 
and IFNγ, among others (Gruys, Toussaint et al. 2005, Crispe 2016). The relevance of 
these early response cytokines were discovered studying products of leukocytes, which 
are the first cells attracted to sites of injury (Heinrich, Castell et al. 1990). Indeed, the 
APR is a quick response with several APPs detectable as early as 4 to 8 hours after LPS 
administration and elevated 24 to 48 hours post stimuli (Gruys, Toussaint et al. 2005). 
 Historically, many APPs have been used as biomarkers for the severity of various 
diseases. For example, C-reactive protein (CRP) has been used as a marker of infection 
and cardiovascular disease (Liu, Bui et al. 2010, Huang, Gulshan et al. 2017), serum 
amyloid A (SAA) for various infections and inflammatory states (Eckersall and Bell 
2010), and haptoglobin (Hp) for lung cancers (Chang, Lai et al. 2016). Although there are 
dozens of known liver-derived APPs, the functions have not all been elucidated.  
Moreover, how changes in many APPs coalesce to have significant biological impact is 
very poorly understood, and most likely, context-dependent.  That said, many individual 
APPs have been shown to modulate immune responses through various mechanisms. 
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Several positive APPs, i.e., those with increasing blood concentrations during the APR, 
are thought to prevent microorganism growth, restore homeostasis, activate complement, 
aid in opsonophagocytosis, scavenge cell remnants and free radicals, and neutralize 
proteolytic enzymes (Tillett and Francis 1930, Gruys, Toussaint et al. 2005, Chami, 
Barrie et al. 2015). Several negative APPs have been shown to reduce blood 
concentration of zinc, iron, and cortisol-binding globulin, among others (Gruys, 
Toussaint et al. 2005, Johnson and Wessling-Resnick 2012), likely interfering with the 
growth and survival of select pathogens.  
 
The Lung-Liver Axis during Pneumonia 
 The activation and functional role of the APR has been shown to be important for 
lung defense during infections. Studies have demonstrated that significant remodeling of 
the liver transcriptome occurs hours after bacterial lung infections (Quinton, Blahna et al. 
2012). The regulation of the hepatic APR gene program is reliant on several known 
transcription factors, of which NF-κB and STAT3 are shown to play significant roles 
during lung infections (Quinton, Blahna et al. 2012). While over 1,000 hepatic gene 
transcripts were altered following a S. pneumoniae lung infection, simultaneous deletions 
of NF-κB RelA and STAT3 in hepatocytes essentially eliminated the APR to the 
pneumonia challenge (Quinton, Blahna et al. 2012). Activation of these transcription 
factors is initiated by early-response cytokines TNFα, IL-1, and IL-6, as IL-6-null mice 
or mice lacking all signaling receptors for TNF and IL-1 have a markedly reduced 
capacity to activate liver STAT3 and NF-κB RelA, respectively, following a bacterial 
  
19
pneumonia challenge in association with reduced APP induction (Quinton, Jones et al. 
2009). These studies support the central role of a lung-liver axis, in which early and local 
responses to respiratory infections remodel the hepatic transcriptome and modulate host 
responses.  
 The physiological mechanisms through which the lung-liver axis provides 
protection during pneumonia is unclear, and pursuit of such information is challenged by 
the large scope of hepatic acute phase changes observed in response to this condition. 
However, studies have now unveiled the protective function of the APR during 
respiratory infections. APR-mice lacking hepatocyte RelA and STAT3 have reduced 
induction of both circulating APPs and those accumulating in the alveolar lining fluid in 
pneumonic mice (Quinton, Blahna et al. 2012, Hilliard, Allen et al. 2015). Additionally, 
these APR-null mice exhibit decreased host defense associated with higher bacterial 
burdens, and increased mortality. Mechanisms implicated in APR-dependent protection 
during lung infections include diminished airspace macrophage activation, and decreased 
complement-mediated opsonization (Quinton, Blahna et al. 2012, Hilliard, Allen et al. 
2015). Hepatocyte STAT3, alone, has been implicated in altering the lung environment 
during endotoxemia, leading to substantially increased pneumonia susceptibility 
(Hilliard, Allen et al. 2015), suggesting that normal liver activity may serve to limit the 
degree to which sepsis (and/or other systemic challenges) predispose to lung infection. 
Consistent with the idea of liver-derived lung protection, IL-6 driven induction of APP 
hepcidin (HAMP) was shown to be important in promoting pulmonary defense and 
preventing bacterial dissemination through iron sequestration (Michels, Zhang et al. 
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2017). But APPs represent only a portion of the numerous liver pathways altered during a 
lung infection (Quinton, Blahna et al. 2012, Weber, Lambeck et al. 2012). While these 
changes may reflect processes supporting APPs synthesis and/or secretion, activation of 
“non-APP” pathways may also include homeostatic measures such as metabolism and 
other forms of adaptation. For instance, S. pneumoniae infections reduce liver cholesterol 
biosynthesis and heighten pneumococcal virulence, possibly by limiting cholesterol-
dependent protection against the injurious toxin pneumolysin (Weber, Lambeck et al. 
2012). Tissue resilience of the liver itself may also represent part of the APR, as 
STAT3/RelA-deficient APR-null mice exhibit increased liver injury during an acute lung 
infection in association with increased mortality (Hilliard, Allen et al. 2015). While the 
significance of the lung-liver axis is now appreciated, coordinating its protective effects 
are only beginning to be elucidated.   
 
Liver Injury in Severe Infection 
 While the liver has a central role in immune regulation, it is a common target of 
dysregulation during infections. In particular, liver injury has prognostic relevance for 
sepsis (Minemura, Tajiri et al. 2014). As such, clinical measures of liver dysfunction are 
a component of the SOFA score (Singer, Deutschman et al. 2016). Liver injury 
commonly occurs during the course of sepsis, with mean incidence in 30-50% of sepsis 
patients (Wang, Yin et al. 2014, Yan, Li et al. 2014). Development of liver dysfunction is 
a strong predictor of morbidity and mortality (Yan, Li et al. 2014, Nesseler, Launey et al. 
2016). Incidence rates of sepsis are higher in patients with pre-existing liver dysfunction 
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or disease (Canabal and Kramer 2008). Even in the setting of pneumonia, modest liver 
injury was associated with negative patient outcomes (Jinks and Kelly 2004, Xu, Ying et 
al. 2018).  
 There are several well-described mechanisms of sepsis-related liver injury. 
Hypoxic hepatitis, known as shock liver, occurs in approximately 10% of septic patients 
and is associated with 50% mortality (Kramer, Jordan et al. 2007, Jager, Drolz et al. 
2012). Shock liver arises from inadequate oxygen concentration due to reduced blood 
flow, decreased oxygen carriers, and microthrombi. Elevated serum transaminases, miR-
122, and keratins are detected just hours after injury, and are indicative of apoptotic and 
necrotic cell death (Roderburg, Benz et al. 2015, Ku, Strnad et al. 2016). Patients develop 
cholesteric hepatic dysfunction resulting from impaired bile formation or decreased bile 
flow. Experiments in mouse models of sepsis show evidence that proinflammatory 
cytokines TNFα and IFNγ alter ion transport systems and promote inflammation, leading 
to impaired bile flow (Spirli, Nathanson et al. 2001). Changes in bile flow contribute to 
the accumulation of bilirubin, altered glucose and lipid metabolism, and vasodilation, 
leading to increased oxidative stress and cell membrane permeability (Trauner, 
Baghdasaryan et al. 2011).  
 Less studied mechanisms of sepsis-related liver injury include immunotoxicity. 
Innate leukocytes are known to be sufficient and necessary to promote liver injury 
(Wang, Yin et al. 2014). Activation of hepatic NKT cells have been linked to increased 
mortality in association with systemic inflammation in murine models of sepsis (Hu, 
Venet et al. 2009). Likewise, Kupffer cells have been shown to drive programmed cell 
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death of hepatic endothelial cells during sepsis (Hutchins, Wang et al. 2013). Several 
mechanisms of cell death by immune cells and immune mediators have been implicated 
in the promotion liver injury. Apoptosis of hepatocytes and endocytosis of apoptotic 
bodies activate Kupffer cells, which upregulate death ligands TNFα, TRAIL, and FasL 
(Canbay, Feldstein et al. 2003). These death ligands are capable of inducing cell death 
receptor-mediated apoptosis (Beg, Sha et al. 1995, Tsutsui, Matsui et al. 1997, Ochi, 
Ohdan et al. 2004), which further promote liver inflammation. Necroptosis, a form of 
programmed cell death dependent on RIP kinases, is also driven by TNFα and Fas-
mediated cell death (Linkermann and Green 2014). Necroptosis and necrosis are 
accompanied by release of cellular constituents, known to elicit significant inflammatory 
responses and promote liver injury (Kaczmarek, Vandenabeele et al. 2013, Huang, 
Tohme et al. 2015, Yamamoto and Tajima 2017).  
 
Aims and Hypothesis 
 Pneumonia and sepsis are distinct but integrally linked public health concerns that 
are a common cause of morbidity and mortality. The mechanisms of protection that limit 
harmful systemic consequences of pneumonia as well as its likelihood in the setting of 
sepsis are unclear. The hepatic APR is a coordinated response to maintain host 
homeostasis during infection, inflammation, and tissue injury. Our laboratory has 
previously revealed the importance of hepatocyte transcription factors STAT3 and NF-κB 
RelA (p65) for the APR during pneumonia or sepsis. Our prior studies utilizing mice with 
hepatocyte-specific deletion of both transcription factors revealed elimination of the acute 
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phase response, impaired host defense, and increased susceptibility to liver injury. 
Therefore, we propose the central hypothesis that hepatic APR transcriptional 
responses are critical for deleterious interactions between pneumonia and sepsis.  
 Previous reports highlight liver dysfunction as an important independent risk 
factor for sepsis mortality (Yan, Li et al. 2014, Nesseler, Launey et al. 2016). Our 
preliminary data allude to the existence of liver-derived homeostatic signals that prevent 
hepatotoxicity from becoming a more prominent feature of pneumonia. While hepatocyte 
transcription factors STAT3 and NF-κB RelA (p65) are essential for acute phase changes, 
our preliminary studies demonstrate that the absence of RelA alone leads to mortality and 
liver injury, possibly due to dysregulation of locally-derived death-promoting signals. 
These findings suggest that RelA activity normally counters pneumonia-induced sepsis 
by preventing programmed hepatocyte cell death, thereby preserving liver homeostasis. 
Given these findings, we hypothesize that RelA-dependent gene programs counter 
damaging signals from hepatic leukocytes to maintain liver homeostasis and limit 
the systemic consequences of pneumonia and sepsis.  
 Our lab has previously shown that activation of the STAT3 transcription factor in 
hepatocytes limits pneumonia susceptibility during endotoxemia, a model of sepsis, but 
the mechanisms whereby this liver APR provides protection are unknown. Sequestering 
iron is a form of nutritional immunity and a first line of defense against bacterial 
infections, which require iron for growth. Based on our previous finding that growth 
conditions in alveolar lining fluid are favorable for bacteria in the absence of liver 
STAT3, we also propose the hypothesis that the liver APR limits pneumonia 
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susceptibility during sepsis by withholding available iron to prevent bacterial 
outgrowth. 
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CHAPTER TWO: MATERIALS AND METHODS 
 
Mouse Models 
 Mouse experiments were performed using C57BL/6 mice, or mice with 
hepatocyte-specific deletions of either NF-κB RelA/p65 or STAT3. This well-established 
system utilizes a Cre-LoxP system driven by an albumin promoter, which results in a 
functional deletion of RelA or STAT3 by 6 weeks of age (Postic and Magnuson 2000). 
Our lab has previously verified the deletion of RelA and STAT3 in the livers of these 
mice models (Quinton, Blahna et al. 2012). Mouse experiments were performed at least 
twice using mice of both sexes, between the ages of 6 and 15 weeks. All animal 
experiments and protocols were approved by Boston University Institutional Animal Care 
and Use Committee (IACUC).  
 
C57BL/6 Mice 
 C57BL/6 mice were purchased directly from Jackson Laboratory, or were from a 
colony maintained by our laboratory.  
 
Hepatocyte RelA-null (hepRelAΔ/Δ) Mice 
 Dr. R.M. Schmid generated and kindly provided our laboratory with RelA-floxed 
mice (RelALoxP/LoxP), which have LoxP sites flanking exons 7-10 of the NF-κB RelA gene 
(Algul, Treiber et al. 2007). Homozygous RelA-floxed mice were crossed with transgenic 
mice purchased from Jackson Laboratory containing a Cre-recombinase under 
transcriptional control of the albumin promoter. The resulting hepRelAΔ/Δ (Alb-Cretg/-
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/RelALoxP/LoxP) mice have hepatocyte-specific deletions of RelA exons 7 through 10. The 
truncated form of RelA prevents nuclear translocation and activation (Carpenter, 
Schroeder et al. 2012). Results from hepRelAΔ/Δ mice were compared to wild type (WT) 
littermates lacking Cre-recombinase (Cre-/-/RelALoxP/LoxP). 
 
Hepatocyte STAT3-null (hepSTAT3Δ/Δ) Mice 
 Dr. S. Akira generated and kindly provided our laboratory with STAT3-floxed 
mice (STAT3LoxP/LoxP), which have LoxP sites flanking exon 21 of the STAT3 gene (Akira 
2000). Homozygous floxed STAT3 mice were crossed with transgenic mice purchased 
from Jackson Laboratory, containing a Cre-recombinase under transcriptional control of 
the albumin promoter. The resulting hepSTAT3Δ/Δ (Alb-Cretg/-/STAT3LoxP/LoxP) mice have 
hepatocyte-specific deletions of STAT3 exon 21. The truncated form of STAT3 lacks a 
tyrosine residue that is necessary for dimerization and activation (Akira 2000). Results 
from hepSTAT3Δ/Δ mice were compared to WT littermates lacking Cre-recombinase 
(Cre-/-/STAT3LoxP/LoxP). 
 
Bacteria and Stimuli 
Generation of Bacterial Stocks 
 Frozen stocks were prepared by growing bacteria overnight on 5% sheep blood 
agar plates (BD Biosciences). Colonies were picked and grown to mid-log phase 
(approximately 4 hours) in sterile lysogeny broth (LB) broth at 37°C and shaking at 300 
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rpm. Bacterial aliquots were mixed with sterile glycerol (final concentration = 16%). 
Aliquots were snap frozen in liquid nitrogen and stored at -80°C until use.  
 
Preparation of Bacteria for In Vivo Experiments 
 Bacteria were streaked on 5% blood agar plates and incubated 12 to 15 hours in 
37°C and 5% CO2. Colonies were picked off the plate and suspended in sterile saline. 
Colony forming unit (CFU) inputs were estimated by optical density and confirmed by 
serial dilution on agar plates. Heat-killed bacteria were prepared by incubating suspended 
bacteria in a 55°C water bath for 45 minutes.  
 
Bacteria and Other Stimuli 
 Bacterial strains were purchased from ATCC: Escherichia coli (serotype 
O6:K2:H1, 19138), Klebsiella pneumoniae (serotype 2, 43816), and Streptococcus 
pneumoniae (serotype 3, 6303). Alpha-Galactosylceramide (αGalCer) was purchased 
from Enzo Life Sciences (BML-SL232) and lipopolysaccharide (LPS-EB from E. coli 
O111:B4) was purchased from InvivoGen (tlrl-eblps).  
 
Infection Models 
Intraperitoneal Injections (I.P.) 
 Mice were administered intraperitoneal injections (i.p.) in the lower right quadrant 
of the abdomen using a 25-gauge needle. Anesthesia for the following in vivo procedures 
and LPS stimulation (0.1 mg/kg diluted in sterile saline) were administered i.p.  
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Intratracheal Instillations (I.T.) 
 Mice were anesthetized by i.p. injection of ketamine (50 mg/kg) and xylazine (5 
mg/kg) in sterile saline. A small incision was made, and the trachea was exposed and 
cannulated with a 24-gauge angiocatheter directed into the left bronchus. A 50 μL bolus 
of bacteria (106 CFU of E. coli, 103 CFU of K. pneumoniae) suspended in sterile saline 
was instilled using a micropipetter. The inoculum was confirmed by plating serial 
dilutions of the bacterial suspension on agar plates and incubating overnight in 37°C.  
 
Intravenous Injections (I.V.) 
 Mice were anesthetized by an i.p. injection of ketamine (50 mg/kg) and xylazine 
(5 mg/kg) in sterile saline. A 100 μL bolus of bacteria or stimuli (106 CFU of E. coli, 106 
CFU of live S. pneumoniae, 107 of heat-killed S. pneumoniae, 2 ug/mouse of αGalCer) 
suspended in sterile saline was administered by tail vein injection using a 27-gauge 
needle.  
 
Endotoxemia-Pneumonia Two-Hit-Model 
 HepSTAT3Δ/Δ and WT mice were administered i.p. 1 mg/kg of LPS 18 hours 
prior to intratracheal instillation of 106 CFU of E. coli.  
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Cecal-Ligation and Puncture Model (CLP) 
 Mice were anesthetized by inhalation of 2 to 5% isoflurane in 100% oxygen. A 
small incision was made through the skin and linea alba. The cecum was exposed, ligated 
with a silk suture, and perforated twice with a 23-guage needle with stool extruded. The 
cecum was replaced in the original position and the incision was closed with sutures and 
skin adhesive glue (Nexaband Liquid, Abbott Laboratories). In Sham mice, the cecum 
was replaced without ligation or puncture. Mice were administered 1 mL of warm saline 
(37°C) by subcutaneous injection. 2 hours after surgery, and every 12 hours thereafter, 
mice were administered subcutaneous injection of buprenorphine (0.05 mg/kg) suspended 
in 1 mL of lactated Ringer’s solution for pain management and imipenem (25 mg/kg) for 
antibiotic treatment. CLP was performed by Dr. J. Kim in the laboratory of Dr. D.G. 
Remick at Boston University School of Medicine. 
 
Neutralization, Blocking, and Depletion Strategies 
 To interrogate the role of NKT cells, mice received i.v. injections of either anti-
Cd1d (Biolegend 123515) or control IgG (Biolegend RTK4530) at a dose of 0.1 
mg/mouse. TNF neutralization was achieved through i.v. administration of 100 l saline 
containing 0.5 mg anti-TNFα (BioXCell BE0058) or control IgG (BioXCell BE0088) at 
the time of challenge. To investigate the role of recruited monocytes, mice received i.p. 
injection of 300 μg/mouse of either anti-Ccl2 (BioXCell BE0185) or control IgG 
(BioXCell BE0091) 24 hours prior to and at the time of challenge. To deplete 
macrophages, mice received i.v. 0.1 mL/10 g body weight of either clodronate- or PBS-
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containing liposomes (Liposoma BV) 24 hours prior to challenges as described by 
manufacturers. To investigate the role of necroptosis, mice received i.v. injections of 
either Nec-1s (Biovision Inc. 2263) at dose of 6.25 mg/kg or vehicle 15 min prior to 
challenge.   
 
Endpoint Collections 
Blood and Tissue Collection 
 Mice were euthanized at indicated time points by isoflurane inhalation overdose. 
After euthanasia, blood was collected from the inferior vena cava with a 25-gauge needle. 
Blood was deposited into MiniCollect Tube Z Serum separator tubes (Greiner BioOne) 
and incubated at room temperature for 30 min for serum, or collected with a heparinized 
needle and kept on ice for plasma. Blood samples were centrifuged at 1500 x g for 15 
min at 4°C. Serum or plasma was collected, aliquoted, and stored at -80°C until future 
analysis.  
 The medial lobe of the liver of each mouse was collected after euthanasia, snap 
frozen in liquid nitrogen, and stored at -80°C until future analysis. Likewise, the left lobe 
of the lung was snap frozen and stored at -80°C after bronchoalveolar lavage.  
 
Bronchoalveolar Lavage (BAL) 
 Mice were euthanized at indicated time points by isoflurane inhalation overdose. 
The inferior vena cava was cut to exsanguinate or blood was collected from the inferior 
vena cava. The thoracic cavity was exposed and the trachea, lungs, and heart were 
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removed en bloc. The trachea was cannulated with a 20-gauge blunt stainless steel 
catheter and secured with a silk suture. Lungs were injected with 1 mL of ice-cold PBS, 
lavage fluid was withdrawn and collected. Lungs were lavaged 10 times, with the first 
wash collected separately. Washes were centrifuged at 300 x g for 5 min at 4°C to 
separate supernatants and cell pellets. The supernatant from the first lavage was aliquoted 
and stored at -80°C until analysis. For select studies, BAL fluid was sent to the laboratory 
of Marianne Wessling-Resnick at Harvard School of Public Health for iron concentration 
measurements.  
 
Bacteriology 
 Blood samples were serially diluted in sterile water, plated on 5% sheep blood 
agar plates, and incubated at 37°C overnight. Colonies were counted and calculated as 
total CFU per mL of blood.  
 
Aminotransferase Assays 
 Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
concentrations were measured using AST and ALT Reagent Set (Point Scientific Inc.). 
100 μL of 10 to 100-fold diluted serum was added to 1 mL of pre-warmed reagent, and 
absorbance was read at one min intervals over 3 min. Concentrations were calculated 
according to manufacturer’s instructions.  
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Immunohistochemistry 
Liver Fixation and Hematoxylin and Eosin (H&E) Staining 
 The left lateral lobe of each mouse was isolated, cut into three sections, and fixed 
in 4% paraformaldehyde (PFA) overnight at 4°C. Tissue sections were placed in tissue 
cassettes and sent to Boston University School of Medicine Experimental Pathology 
Laboratory Service Core for processing and H&E staining.  
 
Lung Fixation and Hematoxylin and Eosin (H&E) Staining 
 After euthanasia, the thoracic cavity was opened and inferior vena cava cut to 
exsanguinate. 5 mL of ice-cold PBS was injected into the right ventricle of the beating 
heart with a needle to perfuse the lungs. The heart was tied off with a suture to prevent 
backflow of blood. The trachea, lungs, and heart was removed en bloc. The trachea was 
cannulated and secured to a 20-gauge catheter. The lungs were filled with 4% PFA at a 
22 cm-height pressure. The trachea was tied off with a suture and lungs were immersed in 
4% PFA overnight at 4°C. The left lobe was cut into three sections, which were placed in 
tissue cassettes, and sent to Boston University School of Medicine Experimental 
Pathology Laboratory Service Core for processing and H&E staining. 
 
Hypoxyprobe-1 Immunohistochemistry Staining 
 Mice were administered 60 mg/kg Hypoxyprobe-1 (hypoxyprobe.com) in sterile 
saline by i.p 1 hour prior to euthanasia. The left lateral lobe of each mouse was isolated, 
cut into three sections, and fixed in 4% PFA overnight at 4°C. Livers were incubated in 
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specified solutions for indicated times and temperatures (Table 1). Tissues were 
embedded in Surgipath Paraplast Plus paraffin (Leica Biosystems) within 24 x 24 x 5 mm 
molds (Fisher Scientific) and cooled overnight at room temperature. Paraffin blocks were 
cooled to 4°C and sectioned into 5 μm thick sections by microtome and placed onto 
microscope slides.  
 Sectioned liver tissues were de-paraffinized using the indicated protocol (Table 
2), and antigen retrieval was performed by low power microwave (5 min, three times) in 
Antigen Unmasking Solution (Vector Laboratories). Slides were cooled for 30 min, 
washed in PBS for 10 min, and endogenous peroxidase was quenched using 3% hydrogen 
peroxide in PBS for 15 min at room temperature. Slides were washed in PBS for 15 min 
and tissue sections were blocked with Mouse on Mouse Blocking Reagent (Vector 
Laboratories) for 60 min following manufacturer’s instructions. Sections were stained 
with Hyproxyprobe-1 MAb1 (hyproxyprobe.com) primary antibody diluted 1:50 in PBS 
for 1 hour at room temperature, and washed in PBS for 10 min. Tissue sections were 
incubated with secondary antibody using the Vectastain ABC HRP Kit, Peroxidase 
(Vector Laboratories) for 30 min at room temperature, washed in PBS for 10 min, and 
developed using DAB peroxidase HRP Substrate Kit (Vector Laboratories) for 1 min. 
Sections were counterstained with hematoxylin, dehydrated (reverse of Table 2), and 
mounted with a coverslip. 
 
 
 
  
34
Solution Incubation Time Temperature 
PBS 30 min On ice 
0.85% NaCl 30 min On ice 
1:1 Ethanol : 0.85% NaCl 30 min Room temperature 
70% Ethanol (2 times) 30 min each Room temperature 
80% Ethanol 45 min  Room temperature 
90% Ethanol 45 min Room temperature 
100% Ethanol (3 times) 30 min each Room temperature 
Xylene (3 times) 30 min each Room temperature 
1:1 Xylene : paraffin 1.5 hr 60°C 
Paraffin (2 times) 1 hr each 60°C, in vacuumn 
Table 1. Paraffin Embedding Protocol. 
 
Solution Incubation Time 
Xylene (2 times) 5 min each 
100% Ethanol (2 times) 2 min each 
90% Ethanol 1 min 
70% Ethanol 1 min 
50% Ethanol 1 min 
Distilled Water 5 min 
Table 2. Deparaffinization Protocol. 
 
Aminotransferase Assays 
Liver RNA Isolation 
 To isolate RNA from livers, a portion of snap frozen livers were homogenized 
using 7 to 9 2.0-mm zirconium oxide Bullet Blender beads (Next Advance) in TRIzol 
(Life Technologies) using manufacturer’s instructions. RNA was cleaned using the 
RNeasy Kit (Qiagen), and RNA samples were stored at -80°C until analysis. 
 
Lung RNA Isolation 
 To isolate RNA from the left lobe of the lungs, snap frozen lungs were 
homogenized using 7 to 9 3.2-mm stainless steel Bullet Blender beads (Next Advance) in 
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buffer RLT (from Qiagen’s RNeasy Kit) using manufacturer’s instructions. RNA was 
isolated using the RNeasy Kit (Qiagen), and RNA samples were stored at -80°C until 
analysis. 
 
RNA Isolation from Sorted Cells 
 To isolated RNA from sorted cells, cells stored in RNAprotect Cell Reagent 
(Qiagen) were thawed to room temperature, disrupted with RLT buffer (Qiagen) and 
homogenized by centrifugation through a QIAshredder (Qiagen) following 
manufacturer’s instructions. RNA was isolated using the RNeasy Kit (Qiagen), and RNA 
samples were stored at -80°C until analysis. 
 
Quantitative Real-Time PCR (qRT-PCR) 
 Quantitative real-time PCR (qRT-PCR) was performed with 10 ng of isolated 
RNA using the StepOne Plus Real-Time PCR System (Thermo Fisher Scientific) and the 
TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific), following manufacturer’s 
suggested protocol. RNA was probed with primers and FAM-labeled probes for TNF 
(Applied Biosystems Mm00443258_m1), CCL2 (Mm00441242_m1), and CXCL10 
(Mm00445235_m1), HAMP (Mm04231240_s1), HP (Mm00516884_m1), HPX 
(Mm00457510_m1), TFR2 (Mm00443703_m1), WNT3A (Mm00437337_m1), SMAD9 
(Mm00649885_m1), SOX17 (Mm00488363_m1). Primer and probe sequences for LCN2, 
GCSF, GMCSF, CXCL11, and CXCL10 are listed in Table 3. Probes were labeled with 
FAM at the 5’ end and Black Hole Quencher-1 at the 3’ end. Each sample was also 
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probed with VIC-labeled eukaryotic 18S rRNA Endogenous Control (Life Technologies 
4319413E). Sample expression values were calculated and presented as fold induction as 
normalized to 18S rRNA, and expressed as compared to control groups.  
 
Gene Forward Primer Reverse Primer TaqMan Probe 
LCN2 ATATGCACAGGTATCCTC 
AAACGTTCCTTCA
GTTCA 
CCACCACGGACTA
CAACA 
GCSF TTCCCCTGGTCACTGTCAGC 
CACAGCTTGTAGG
TGGCACAC 
ACCATCCTTGCCT
CTGCCCCGAAG 
GMCSF ATTTACTTTTCCTGGGCATTGTGG 
CAGGAGGTTCAGG
GCTTCTTTG 
TACAGCCTCTCAG
CACCCACCCGC 
CXCl1 CAGAGATCGAGAAAGCTTCTGTA 
TCCTGGCACAGAG
TTCTT ATT 
CGAGTAACGGCTG
CGACA 
Table 3. List of qRT-PCR Primer and Probe Sequences. 
 
Microarray 
 Total liver RNA quality of each sample was determined using the Agilent 
Bioanalyzer, followed by microarrays using Affymetrix GeneChip Mouse Gene 2.0 ST 
Arrays. Analysis and microarrays were performed at the Boston University Microarray 
and Sequencing Resource. After data normalization, filtering, and processing, fold 
changes were calculated between experimental groups. Gene expression differences 
between the indicated groups were considered statistically significant when False 
Discovery Rate (FDR) q < 0.05. Ingenuity Pathway Analysis (Qiagen Bioinformatics) 
were used to identify molecular, cellular, or functional pathways.  
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RNA Sequencing (RNA-Seq) 
 Total lung RNA quality of each sample was determined using the Agilent 
Bioanalyzer, and the Illumina NextSeq 500 system for whole transcriptome RNA 
sequencing was performed. A high output of 400M single, 75-base paired end length 
reads were generated. RNA amplification, library preparation, and sequencing were 
performed at the Boston University Microarray and Sequencing Resource. After data 
normalization, filtering, and processing, fold changes were calculated between 
experimental groups by the Microarray and Sequencing Resource and Dr. M.R. Jones. 
Gene expression differences between the indicated groups were considered statistically 
significant when FDR q < 0.05. 
 
Protein Isolation and Measurements 
Protein Isolation 
 Snap frozen liver lobes were homogenized using 7 to 9 2.0-mm zirconium oxide 
Bullet Blender beads (Next Advance) in protein extraction buffer. Homogenates were 
incubated on ice for 15 min with occasional vortexing. After centrifugation for 20 min at 
15,000 x g and 4°C, supernatants were aliquoted and stored in -80°C until analysis.  
 
Bicinchoninic Acid (BCA) Assay 
 Concentrations of total protein isolated from liver homogenates were determined 
by a BCA assay (Sigma-Aldrich) using bichinchoninic acid and copper (II) sulfate 
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solution. Total protein concentration were calculated using manufacturer’s instructions by 
comparing sample to BSA protein standards at 0, 0.2, 0.6, and 0.9 mg/mL concentrations.  
 
Immunoblot 
 Protein samples were diluted to 20 μg in NuPage lithium dodecyl sulfate sample 
buffer (Life Technologies), NuPage Reducing Agent (Life Technologies), and ultrapure 
water, and heated for 10 min at 70°C. Immunoblots were performed using the NuPAGE 
Bis-Tris Gel system and tank.15 μL of samples and protein standards (Novex Sharp, Life 
Technologies) were loaded onto a NuPAGE 4-12% Bis-Tris gel (Novex by Life 
Technologies). 1x MOPS SDS running buffer was added and the gel was run for 50 min 
at 200V. Protein was transferred onto an immobilon-P polyvinylidene fluoride (PVDF) 
membrane (Millipore) in 1x NuPage transfer buffer (Life Technologies) with 10% 
methanol at 30V for 1 hour. Membranes were blocked in 5% non-fat dry milk in tris-
buffered saline with Tween 20 (TBS-T) for 1 hour at room temperature with agitation, 
followed by three 10-min washes in TBS-T. Membranes were probed using primary 
antibodies from Cell Signaling Technology (Table 4) diluted in 10 mL blocking buffer 
with agitation. After three washes, anti-rabbit HRP-conjugated secondary antibody (Cell 
Signaling 7074) diluted 1:2000 in 10 mL blocking buffer was added to membranes for 1 
hour at room temperature with agitation. Membranes were visualized using the ECL 
Prime Western Blotting Detection System (Sigma-Aldrich) on film (GE Healthcare) 
following manufacturer’s instructions. Membranes were stripped with Re-Blot Plus Mild 
antibody stripping solution(Millipore) before blocking and probing of the next primary 
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antibody. Densitometry was performed using Image Processing and Analysis in Java 
(ImageJ, NIH).  
 
Antibody Species, Clone Dilution Incubation Time 
Company (Cat. 
No) 
Cleaved 
Caspase-3 
Rabbit 
monocolonal, 
Asp175, 5A1E 
1:000 Overnight at 4°C 
Cell Signaling 
Technologies 
(9664) 
Cleaved 
Caspase-8 
Rabbit 
monocolonal, 
Asp387, D5B2 
1:000 Overnight at 4°C 
Cell Signaling 
Technologies 
(8592) 
Pan-Actin Rabbit Polyclonal 1:000 1 hr at room temperature 
Cell Signaling 
Technologies 
(4968) 
Table 4. List of Immunoblot Antibodies. 
 
Multi-Plex Bead Array 
 Serum protein concentrations of CCL2, CCL3, CCL4, CCL11, CXCL1, CXCL2, 
CXCL5, CXCL10, IL-1α, IL-1β, IL-6, IL-10, IL-17a, IL-23p19, G-CSF, IFNγ, and TNFα 
were measured by using a Mouse Magnetic Luminex Assay (R&D Systems LXSAMSM) 
on the Bio-Plex 200 multiplexing analyzer system following manufacturer’s instructions.  
 Plasma and lung homogenate concentrations of CCL2, CCL19, CXCL1, CXCL2, 
G-CSF, GM-CSF, IL-1α, IL-6, IL-10, osteopontin, podocalyxin, and uPAR were 
measured using the Mouse Magnetic Luminex Assay system (R&D Systems 
LXSAMSM).  
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Flow Cytometry and Cell Sorting 
 Cells were resuspended in 100 μL FACS buffer with Fc block (TruStain FcX 
antibody, Biolegend). Cell surface markers were stained with 20 μL of diluted antibodies 
(Table 5), incubated on ice for 30 min, covered from light. Cells were washed with 4 mL 
of PBS, pelleted by centrifugation at 300 x g, 4°C for 5 min, and resuspended in 400 μL 
FACS buffer. Cells were kept on ice until flow cytometry analysis on the BD LSRII or 
cell sorting by an operator on the FACSAria II SORP at Boston University Flow Core 
Facility. NKT cells, NK cells, Kupffer cells, and monocytes were identified by surface 
markers in Table 6. Single stained cells or bead controls (UltraComp eBeads, 
Thermofisher) were utilized for compensation and gating in the FACS Diva program. 
Flow cytometry analysis was performed on FlowJo (Version 10). Sorted cells were 
pelleted and resuspended in 300 μL RNAprotect Cell Reagent (Qiagen) and stored at -
80°C until RNA isolation. 
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Antibody Clone Fluorophore Dilution Company (Cat. No.) 
CD45 30-F11 PE-Cy7 1:1000 Biolegend (103113) 
CD3 17A2 APC 1:50 Biolegend (100236) 
NK1.1 PK136 FITC 1:100 Biolegend (108705) 
NKp46 29A1.4 BV605 1:50 Biolegend (137619) 
CD1d-
loaded 
tetramer 
PBS-57 PE 1:50 
NIH Tetramer 
Core Facility 
(20670) 
F4/80 RTK2758 APC-Fire750 1:100 Biolegend (123151) 
CD11b M1/70 BUV395 1:100 BD Horizon (563553) 
Ly6C HK1.4 BV785 1:100 Biolegend (128041) 
7AAD N/A N/A 5 μL / sample 
Biolegend 
(420404) 
Table 5. List of Flow Cytometry Antibodies. 
 
Cell Type Surface Markers 
Kupffer Cells 7AAD-/CD45+/F4/80+ 
Monocytes 7AAD-/CD45+/CD11b+/Ly6C+ 
NK Cells (C57/Bl6) 7AAD-/CD45+/CD3-/NK1.1+ 
NK Cells (hepRelAΔ/Δ) 7AAD-/CD45+/CD3-/NKp46+ 
NKT Cells (C57/Bl6) 7AAD-/CD45+/CD3+/NK1.1+ 
NK Cells (hepRelAΔ/Δ) 7AAD-/CD45+/CD3-/CD1d-loaded Tetramer+ 
Table 6. Cell Populations and Surface Markers for Flow Cytometry. 
 
Reagents and Buffer Recipes 
- Phosphate-buffered saline (PBS, Gibco, ThermoFisher Scientific)  
- Hank’s balanced salt solution (HBSS, ThermoFisher Scientific)  
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- Protein extraction buffer: 2 mM Tris at pH 7.4, 50 mM sodium chloride, 0.5% sodium 
deoxycholate, 2% NP-40, 0.2 sodium dodecyl sulfate (SDS), and 1x Roche Complete 
Protease Inhibitor in deionized water 
- Methanol (Sigma-Aldrich) 
- Tris-buffered saline-Tween-20 (TBS-T): 25 mM Tris at pH 8.0, 125 mM sodium 
chloride, 0.1% Tween-20 in deionized water 
- Blocking buffer: 5% non-fat dry milk in TBS-T 
- NuPAGE MOPS SDS running buffer (Invitrogen, ThermoFisher Scientific) 
- NuPAGE Transfer buffer (Invitrogen, ThermoFisher Scientific) 
- 4% paraformaldehyde (PFA): 10 mL 16% PFA (Ted Pella, Inc), 4 mL 10x PBS, 26 mL 
distilled water 
- Sodium Chloride (0.9% NaCl, Saline, Baxter Healthcare Corporation) 
- Ethyl alcohol (Fisher Chemical): 90-50% ethanol diluted in distilled water 
- Xylenes (Fisher Chemical) 
- Hematoxylin stain (Ricca Chemical Company) 
- Roswell Park Memorial Institute 1640 Media (RPMI1640, Gibco, ThermoFisher 
Scientific) 
- Collagenase solution: 0.05% collagenase/dispase (Sigma-Adrich), 0.01% trypsin 
inhibitor (soybean, Gibco, ThermoFisher Scientific) in RMPI1640; 15 mL per sample 
- Normo-osmotic Percoll solution: 37 mL Percoll Plus (GE Healthcare, Sigma-Aldrich), 
2.88 mL 10x HBSS, 480 μL sodium bicarbonate solution (7.5%, Gibco, ThermoFisher 
Scientific); for 6 samples  
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- 33% Percoll solution: 33 mL normo-osmotic Percoll solution, 66 mL RPMI1640, 1 mL 
heparin (1000 U/mL); for 6 samples  
- Red Blood Cell Lysing Buffer Hybri-Max (Sigma-Aldrich) 
- Fluorescence-Activated Cell Sorting (FACS) buffer: 0.5% fetal bovine serum (FBS), 2 
mM EDTA in PBS; Sterilized by filter 
 
Statistics 
 Statistical analyses were performed using GraphPad Prism 8.0. All data are 
presented as mean ± SEM. Two-group comparisons were made using a student’s t test. 
Multiple group comparisons were made using one- or two-way analysis of variance 
(ANOVA) followed by a Tukey multiple comparisons test. All data were tested for 
normality (Shapiro-Wilk test) and equal variance (F-test or Spearman’s test). Data that 
were not normally distributed were log transformed before statistical analysis. Results 
were considered significant if p < 0.05. 
 
.
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CHAPTER THREE: HEPATIC NF-KAPPAB RELA ACTIVATION IS 
REQUIRED FOR HEPATOPROTECTION DURING PNEUMONIA AND SEPSIS 
 
Rationale 
 Sepsis is a complex disorder that arises as a dysregulated host response to 
infection, and is associated with acute organ dysfunction (Singer, Deutschman et al. 
2016). This condition remains a common and deadly public health concern with lasting 
morbidity and considerable economic consequences (Paoli, Reynolds et al. 2018). Sepsis 
is the leading cause of mortality in hospitalized patients, with annual rates of incidence 
steadily increasing worldwide (Walkey, Lagu et al. 2015). Respiratory infections, which 
are the most common cause of sepsis (Mayr, Yende et al. 2014), represent the greatest 
disease burden worldwide, and account for the most infection-related deaths (Quinton, 
Walkey et al. 2018). Sepsis can occur when bacteria disseminate from the lungs and 
compromise non-pulmonary tissue resilience and vascular homeostasis (Wunderink and 
Walley 2014). While pneumonia and sepsis are intimately linked, it remains unclear 
whether and how extra-pulmonary signals actively fortify tissue protection during lung 
infections as a means to limit the progression of the former towards the latter.  
 The hepatic acute phase response (APR) is a hallmark of sepsis, pneumonia, and 
other inflammatory conditions (Gabay and Kushner 1999). This event is typified by 
changes in circulating acute phase proteins (APPs) such as C-reactive protein (Gabay and 
Kushner 1999), which are clinically relevant disease biomarkers. However, most hepatic 
gene programs altered during pneumonia do not, in fact, encode APPs (Quinton, Blahna 
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et al. 2012), implicating other biological pathways as an important aspect of the APR. 
Our previous studies in APR-null mice, lacking both the NF-κB RelA and STAT3 
transcription factors in hepatocytes, revealed immune defects and mortality in the settings 
of pneumonia and sepsis (Quinton, Jones et al. 2009, Quinton, Blahna et al. 2012, 
Hilliard, Allen et al. 2015). Interestingly, liver injury was also observed in APR-null mice 
during pneumonia, suggesting that hepatoprotection is an inducible process that curbs the 
systemic consequences of lung infections (Hilliard, Allen et al. 2015). But whether 
hepatocytes launch countermeasures against immunotoxic signals during infection 
remains unclear. 
 Both infection and organ dysfunction are defining characteristics of sepsis 
(Singer, Deutschman et al. 2016), and the liver is one of several such threatened organs 
(Wang, Yin et al. 2014). Indeed, liver injury is a significant risk factor of sepsis 
morbidity and mortality (Yan, Li et al. 2014, Nesseler, Launey et al. 2016), and its 
underlying causes likely extend beyond hypoxic hepatitis and cholestasis to include less-
known triggers such as immunotoxicity and dysregulated cell death (Hu, Venet et al. 
2009, Hutchins, Wang et al. 2013). Meanwhile, host pathways that limit hepatotoxicity in 
response to infection represent a major knowledge gap. Given prior evidence of NF-κB 
RelA in curbing hepatocyte injury (Beg, Sha et al. 1995, Geisler, Algul et al. 2007), we 
hypothesized that RelA-dependent acute phase changes fortify liver tissue resilience in 
the settings of pneumonia and sepsis.   
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Results 
3.1 Hepatoprotection during pneumonia is ReA-dependent 
 Prior investigations in mice lacking both STAT3 and RelA in hepatocytes 
indicated that the combined presence of these transcription factors is required for liver 
acute phase changes during pneumonia (Quinton, Jones et al. 2009, Quinton, Blahna et al. 
2012, Hilliard, Allen et al. 2015, Hilliard, Allen et al. 2015). Additionally, these APR-
null mice exhibited signs of severe hepatotoxicity (Hilliard, Allen et al. 2015), 
demanding a better understanding of the signals that actively fortify liver tissue integrity 
during infection. To distinguish the functional contributions of STAT3 vs. RelA with 
regards to hepatoprotection during pneumonia, we compared results from mice lacking 
one or the other in hepatocytes. Littermate control (WT) or mutant (hepSTAT3Δ/Δ or 
hepRelAΔ/Δ) mice were infected i.t. with 106 CFU of E. coli. Despite the acute (24-hour 
infection) design and typically non-lethal dose of E. coli selected for this study, we 
observed significant mortality in mutant mice lacking hepatocyte RelA (Figure 1A). The 
surviving hepRelAΔ/Δ mice exhibited significant liver injury based on elevated 
concentrations of serum ALT 24 hours after the pneumonia challenge (Figure 1A). In 
contrast, no evidence of liver injury or mortality was observed in hepSTAT3Δ/Δ mice 
under the same conditions (Figure 1B). Although both transcription factors are necessary 
components to induce the hepatic APR, these results suggest that RelA is primarily 
responsible for hepatoprotective signals elicited by pneumonia. Interestingly, RelA 
targeting had no effect on bacteremia (Figure 2A). Also, liver injury was not 
significantly elevated in hepRelAΔ/Δ mice without detectable bacteremia, despite a 
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noticeable trend (Figure 2B). However, the effect of genotype was far more robust in 
mice with positive blood cultures (Figure 2B). These results suggest that pneumonia-
induced liver injury following i.t. E. coli may be largely attributable to extrapulmonary 
dissemination. 
 
 
Figure 1. Hepatoprotection during pneumonia is RelA-dependent. 
106 CFU of E. coli was instilled i.t. into 15 week-old mice lacking either (A) NF-κB RelA (hepRelAΔ/Δ) or 
(B) STAT3 (hepSTAT3Δ/Δ) in hepatocytes, and results were compared to littermate controls (WT). Survival 
is illustrated over a 24 hour period. Liver injury was assessed by serum ALT and AST concentrations 24 
hours after i.t. E. coli. * p < 0.05 vs. WT; n = 4 to 6 per group. 
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Figure 2. Bacteremia following pneumonia increases liver injury in the absence of 
RelA. 
(A) Blood bacterial burdens were quantified in WT or hepRelAΔ/Δ mice 24 hours after i.t. E. coli. The 
dotted line represents the limit of detection.  (B) Serum ALT levels were compared in WT or hepRelAΔ/Δ 
mice with and without detectable bacteremia 24 hours after i.t. E. coli. * p < 0.05 vs. WT; n = 3 to 4 per 
group.  
 
3.2 RelA-dependent hepatoprotection extends beyond pneumonia 
 To determine whether the aforementioned effect of hepatocyte RelA targeting was 
specific to pneumonia induced by E. coli infection, we challenged mice intratracheally 
(i.t.) or intravenously (i.v.) with additional stimuli (Figure 3). Intratracheal infections 
with live K. pneumoniae (103 CFU) or S. pneumoniae (106 CFU) were sufficient to elicit 
severe hepatotoxicity in hepRelAΔ/Δ mice but not WT controls (Figure 3A, 3B). Similar 
outcomes were observed in hepRelAΔ/Δ mice following i.v. E. coli (106 CFU) or S. 
pneumoniae (106 CFU) (Figure 3C, 3D), as well as non-infectious challenges with heat 
killed S. pneumoniae (107 CFU i.v.) or lipopolysaccharide (LPS) (0.1 mg/kg i.p.) (Figure 
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3E, 3F). Following the i.v. E. coli challenge, liver injury was also confirmed 
histologically (Figure 4). Together, these results indicate that hepatocyte RelA is 
indispensable for hepatoprotection in settings of infection or inflammation, and that liver 
injury is not restricted to that induced by live bacteria.  
 
 
Figure 3. RelA-dependent hepatoprotection extends beyond pneumonia. 
Serum ALT concentrations were measured in hepRelAΔ/Δ or WT mice challenged with (A) i.t. K. 
pneumoniae (103 CFU), (B) i.t. S. pneumoniae (106 CFU), (C) i.v. E. coli (106 CFU), (D) i.v. S. 
pneumoniae (106 CFU), (E) i.p. lipopolysaccharide (0.1 mg/kg), or (F) i.v. heat killed S. pneumoniae (107 
CFU). * p < 0.05 vs. WT; n = 3 to 12 per group. 
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Figure 4. Bacteremia induces liver injury in the absence of RelA. 
Livers were collected 24 hours after i.v. E. coli and processed for histological analysis by hematoxylin and 
eosin (H&E) staining. Representative images are shown for each genotype. Scale bar: 75 μm. 
 
3.3 Aged livers are more vulnerable to liver injury 
 As shown above substantial liver injury occurred in hepRelAΔ/Δ mice following 
i.v. E. coli, and curiously, the degree of injury was associated with age. 10-18 week old 
hepRelAΔ/Δ mice exhibited significantly more intense liver injury as measured by serum 
ALT, and bacteremia (Figure 5). Thus, while we do not detect an overall effect of liver 
genotype on bacteremia when combining mice of all ages used (7-18 weeks), these data 
support the concept that aging livers have a greater demand for hepatoprotection and 
systemic defense.  
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Figure 5. Hepatotoxicity and bacteremia are exacerbated in older mice in the 
absence of hepatocyte RelA. 
WT and hepRelAΔ/Δ mice were challenged with i.v. 106 CFU of E. coli for 24 hours. (A) Survival, (B) 
serum ALT, and (C) blood bacterial burdens were compared between 7-9 and 10-18 week old mice. The 
dotted line represents the limit of detection. *p < 0.05 compared to 7-9 week old mice; n = 10 to 24 per 
group.  
 
3.4 Liver injury during pneumonia and sepsis is associated with increased apoptosis 
 Studies using RelA knockout mice demonstrated TNFα-dependent liver failure 
and death during gestation (Beg, Sha et al. 1995). Furthermore, hepatocyte-specific 
deletion of RelA can render mice vulnerable to liver injury by administration of TNFα 
(Geisler, Algul et al. 2007), which can induce extrinsic apoptosis through death receptor 
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signaling. To determine the relationship between liver injury and apoptosis in hepRelAΔ/Δ 
mice in the setting of live infection, we measured active caspase levels in liver specimens 
collected during pneumonia and/or bacteremia. We observed substantially increased 
levels of cleaved caspase-3 (a pan-marker of apoptosis) and cleaved caspase-8 (a marker 
of extrinsic apoptosis) in the livers of hepRelAΔ/Δ mice compared to WT counterparts 16 
hours after i.t. E. coli (Figure 6A). Similar results were observed in livers from 
hepRelAΔ/Δ mice following i.t. K. pneumoniae and i.v. S. pneumoniae (Figure 6B, 6C), 
implicating dysregulated extrinsic apoptosis as a mechanism promoting hepatotoxicity in 
the absence of hepRelA.  
 Our ability to measure high levels of serum aminotransferases in pneumonic and 
bacteremic hepRelAΔ/Δ mice suggests a loss of plasma membrane integrity, which is 
consistent with necrotic cell death. Additionally, ligands such as TNF promoting 
extrinsic apoptosis can also induce programmed necrosis (necroptosis) through the 
interaction of RIPK1, RIPK3, and MLKL (Eguchi, Wree et al. 2014). To determine 
whether necroptosis contributes to hepatotoxicity, we treated hepRelAΔ/Δ mice with Nec-
1s, a selective inhibitor of RIPK1 (Filliol, Piquet-Pellorce et al. 2016), prior to an i.v. S. 
pneumoniae (Figure 7A). Nec-1s did not reduce serum ALT concentrations in 
hepRelAΔ/Δ mice.   
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Figure 6. Liver injury in hepRelAΔ/Δ mice is associated with apoptosis. 
HepRelAΔ/Δ or WT mice were challenged with: (A) i.t. E. coli (106 CFU) for 16 hours; (B) i.t. K. 
pneumoniae (103 CFU) for 48 hours intravenously; or (C) i.v. S. pneumoniae (106 CFU) for 24 hours. 
Livers were collected and active caspase -3 and -8 were determined in liver tissue homogenates by 
immunoblot. Densitometric analyses are shown as caspase/pan-actin ratios. * p < 0.05 vs. WT. 
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Hypoxia is associated with hepatocyte necrosis during sepsis (Bantel and Schulze-
Osthoff 2009), and hepatocytes have been shown to produce increased levels of TNFα 
following hypoxia in settings such as bacteremia (Loftis, Johanns et al. 2000, Spencer, 
Zhou et al. 2013). To determine whether livers of hepRelAΔ/Δ mice undergo hypoxic 
stress during infection, we probed for Hypoxyprobe-1 adducts in livers of mice 
challenged with i.v. E. coli (Figure 7B). Differences in hypoxia levels were not detected 
histologically. Together, these data suggest that liver injury is not a result of exaggerated 
necroptosis or hypoxia.   
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Figure 7. Liver injury in hepRelAΔ/Δ mice is not associated with necroptosis or 
hypoxia. 
(A) Serum ALT concentrations were measured in hepRelAΔ/Δ mice pre-treated with Nec-1s or vehicle and 
challenged with i.v. heat killed S. pneumoniae for 24 hours (n = 3 per group). (B) Livers were collected 24 
hours after i.v. E. coli and 1 hour after i.p. Hypoxyprobe-1. Livers were processed and probed for signs of 
hypoxia. Representative images are shown for each genotype. Scale bar: 75 μm. 
 
3.5 Liver apoptosis is the absence of RelA is TNF-dependent 
 Serum levels of TNFα have been linked to hepatotoxicity (Pryhuber, Huyck et al. 
2005, Manco, Marcellini et al. 2007), and this cytokine can be produced by multiple cells 
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in the liver, including NKT cells, Kupffer cells, and monocytes (Liaskou, Wilson et al. 
2012). Our observation of enhanced liver apoptosis in our current study combined with 
previous studies in RelA-deficient mouse models (Beg, Sha et al. 1995, Geisler, Algul et 
al. 2007) supports a pathological role for TNFα and/or related pro-apoptotic ligands 
during pneumonia and sepsis that is countered by RelA-dependent gene programs in the 
liver. To determine the direct influence of TNFα on liver injury during infection, 
hepRelAΔ/Δ mice and WT controls were challenged i.v. with S. pneumoniae in the 
presence of a neutralizing TNF antibody or control IgG (Figure 8A). As expected, S. 
pneumoniae caused severe liver injury in hepRelAΔ/Δ mice treated with isotype control 
antibody. However, hepatotoxicity was eliminated in hepRelAΔ/Δ mice treated with 
TNFα-neutralizing antibody (Figure 8A). Additionally, following the S. pneumoniae 
challenge, cleaved caspase-3 and -8 were concomitantly decreased in livers from 
hepRelAΔ/Δ mice treated with TNFα-neutralizing antibody (Figure 8B). Together, these 
findings suggest that TNFα is a critical upstream driver of hepatotoxicity in the absence 
of RelA. 
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Figure 8. Liver injury TNFα-dependent in the absence of RelA. 
(A) Serum ALT was measured in hepRelAΔ/Δ or WT mice challenged i.v. for 24 hours with 106 CFU of S. 
pneumoniae in the presence of an isotype antibody or TNF-α neutralizing antibody. n = 3 to 4 (B) Livers 
were collected 24 hours after i.v. S. pneumoniae, and the presence of activated caspase -3/-8 in liver 
homogenates was measured by immunoblot. Densitometric analyses are shown as caspase/pan-actin ratios. 
* p < 0.05 vs. WT.  
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3.6 Liver TNF is increased after infection in the absence of hepatocyte RelA 
 In order to investigate the liver as a potential source of TNFα, we measured 
TNF mRNA in WT and hepRelAΔ/Δ mice 0, 6, and 24 hours after i.v. S. pneumoniae. 
Liver TNFα mRNA induction was significantly elevated following i.v. S. pneumoniae, 
and this response was further exaggerated in livers of hepRelAΔ/Δ mice compared to WT 
24 hours after S. pneumoniae challenge (Figure 9A). In order to identify potential hepatic 
cellular sources of TNFα, we challenged WT mice with i.v. S. pneumoniae or saline for 
24 hours, isolated mononuclear cells from whole liver tissue enzymatic digests, and 
sorted several candidate cell populations by flow cytometry for mRNA analysis: NKT 
cells (CD45+/CD3+/NK1.1+), NK cells (CD45+/CD3-/NK1.1+), Kupffer cells 
(CD45+/F4/80Hi/CD11b+), and monocytes (CD45+/F4/80Lo/CD11bHi/Ly6CHi). However, 
TNFα was unaffected by bacteremia in our selected panel of leukocytes in WT mice at 
this time point (Figure 9B), suggesting alternative cell types as the primary source(s) of 
liver TNF.   
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Figure 9. TNF transcripts are increased in livers after infection. 
TNFα mRNA induction was measured by qRT-PCR in (A) whole liver tissues of hepRelAΔ/Δ or WT mice 
0, 6, and 24 hours after i.v. S. pneumoniae or (B) NKT cells (CD45+ CD3+ NK1.1+), NK cells (CD45+, 
CD3-, NK1.1+), Kupffer cells (CD45+ F4/80Hi CD11b+), and monocytes (CD45+ F4/80 Lo CD11bHi, Ly6CHi) 
sorted from liver tissues of WT mice 24 hours after i.v. S. pneumoniae. * p < 0.05 vs. WT, # p < 0.05 vs. 0 
hour, n = 3 to 5 per group. 
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3.7 NKT cell activity is sufficient for hepatotoxicity 
 As previous studies have identified NKT cells as a potential source of liver injury 
during sepsis (Hu, Venet et al. 2009), we next determined the influence of this cell type 
on liver injury in our vulnerable hepRelAΔ/Δ mice. I.v. E. coli was sufficient to 
significantly induce activation of liver NKT cells (CD45+/CD3+/αGalCer-loaded CD1d 
tetramer+) in WT mice based on CD69 surface expression (Figure 10A).  
 To determine whether NKT cell activity is sufficient to induce liver injury in the 
absence of RelA, WT and hepRelAΔ/Δ mice were challenged with GalCer, which is a 
well-established specific activator of NKT cells. As with our other experimental systems 
(Figure 3), NKT cell stimulation caused substantial liver injury in hepRelAΔ/Δ mice 
(Figure 10B). Moreover, this effect was completely abrogated by TNF neutralization 
(Figure 10C), consistent with our observations following i.v. S. pneumoniae (Figure 8).  
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Figure 10. NKT cell activity is sufficient to cause hepatotoxicity in hepRelAΔ/Δ mice. 
(A) Mice were challenged i.v. with 106 CFU of E. coli for 24 hours. Single cell suspensions of 
mononuclear cells were generated from whole liver tissues. NKT cells (CD45+/CD3+/ α-galactoceramide 
(αGalCer)-loaded CD1d tetramer+) were identified by flow cytometry and CD69+ surface expression was 
measured as an activation marker. * p < 0.05 vs. saline, n = 2 to 3 per group. Serum ALT was measured (B) 
in hepRelAΔ/Δ or WT mice challenged i.v. for 24 hours with 2 μg α-GalCer or vehicle (*p < 0.05 vs. vehicle 
hepRelAΔ/Δ, n = 3 to 6 per group), and (C) in αGalCer-treated mice co-instilled with control IgG or anti-
TNFα neutralizing antibody (* p < 0.05 vs. anti-TNFα hepRelAΔ/Δ, n = 3 to 6 per group).  
 
3.8 NKT cell activity is not necessary for hepatoprotection 
 To investigate contributions of NKT cell activity to immunopathology during 
infection, anti-CD1d, a well-established means to pharmacologically block NKT cell 
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activity in vivo (Rhee, Carlton et al. 2003), was co-instilled i.v. with 106 CFU of E. coli in 
WT and hepRelAΔ/Δ mice. However, blocking NKT cell activation with anti-CD1d 
during bacteremia significantly compromised anti-bacterial defense, as evidenced by 
greater bacterial burdens in the blood of anti-CD1d-treated mice compared to isotype-
treated controls (Figure 11A). While NKT cells have been identified as an important 
mediator of defense in other settings (Liaskou, Wilson et al. 2012), this is the first 
evidence to our knowledge that this cell type is required for systemic defense against E. 
coli. In order to circumvent the confounding effects of differential bacterial loads after 
NKT cell blockade, we repeated this experiment utilizing non-infectious heat killed S. 
pneumoniae, which is equally effective at causing liver injury in hepRelAΔ/Δ mice 
(Figure 11B). Under these conditions, NKT cell blockade had no protective effect on 
liver injury in hepRelAΔ/Δ mice (Figure 11B). Instead, anti-CD1d increased serum ALT 
levels, strongly arguing against NKT cell activity as the sole source of injury under these 
conditions. These data suggest that NKT cell activity is sufficient but not necessary for 
liver injury in the absence of RelA-dependent hepatoprotection. 
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Figure 11. NKT cell activity is not necessary for hepatotoxicity in hepRelAΔ/Δ mice. 
(A) Blood bacterial burdens were measured 7 hours after i.v. 106 CFU of E. coli in wild type mice treated 
with control IgG or an anti-CD1d antibody blocking NKT cell activity. * p < 0.05 vs. IgG. (B) Serum ALT 
was measured in hepRelAΔ/Δ or WT mice challenged with i.v. 107 CFU of heat killed S. pneumoniae for 
24h hours. * p < 0.05 vs. WT, n = 3 to 6 per group. 
 
3.9 Kupffer cells and recruited monocytes are not required for liver injury in hepRelAΔ/Δ 
mice 
 To determine other immunological effects of liver RelA deficiency during 
bacteremia, we measured serum cytokine and chemokine concentrations utilizing a 
multiplex bead array for 17 inflammation-relevant cytokines: CCL2, CCL3, CCL4, 
CCL11, CXCL1 CXCL2, CXCL5, CXCL10, IL-1α, IL-1β, IL-6, IL-10, IL-17a, IL-
23p19, G-CSF, IFNγ, and TNFα. CCL2 and CXCL10 were the only two significantly 
elevated in mutant mice as compared to their WT counterparts 24 hours after i.v. S. 
pneumoniae (106 CFU) (Figure 12A). Concomitantly, both chemokines were also 
increased at the mRNA level in liver tissues collected from mice (Figure 12B, 12C). 
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Both CCL2 and CXCL10 contribute to the recruitment of monocytes to sites of infection 
(Deshmane, Kremlev et al. 2009, Petrovic-Djergovic, Popovic et al. 2015), prompting us 
to consider the roles of both resident (Kupffer cells) and recruited macrophages and 
monocytes in the context of hepatic RelA deficiency. 
 To determine the impact of monocyte recruitment on hepatotoxicity, WT and 
hepRelAΔ/Δ mice were administered neutralizing CCL2 antibody and heat killed S. 
pneumoniae for 6 hours. CCL2 neutralization, which is sufficient to block liver monocyte 
recruitment (Teng, Han et al. 2017), had no significant effect on liver injury in 
hepRelAΔ/Δ mice (Figure 12D). Meanwhile, we also tested the effect of i.v. clodronate-
encapsulated liposomes, a well-established approach for depleting Kupffer cells (Van 
Rooijen and Sanders 1996). Similar to the results observed following anti-CCL2, 
clodronate administration had no effect on S. pneumoniae-induced bacteremia (Figure 
12E). Together, these results suggest that neither Kupffer cells nor recruited monocytes 
are required for hepatotoxicity in bacteremic hepRelAΔ/Δ mice. 
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Figure 12. Kupffer cells and recruited monocytes are dispensable for hepatotoxicity 
in hepRelAΔ/Δ mice. 
(A) Serum concentrations of the indicated cytokines and chemokines were measured in serum collected 
from hepRelAΔ/Δ or WT mice 24 hours after i.v. S. pneumoniae (106 CFU). (n = 10 per group). mRNA 
levels of (B) CCL2 or (C) CXCL10 were measured by qRT-PCR in whole liver tissues of hepRelAΔ/Δ or 
WT mice 0, 6, and 24 hours after i.v. S. pneumoniae. (n = 3 to 5 per group) Serum ALT was measured in 
hepRelAΔ/Δ or WT mice (D) co-instilled i.v. with IgG control or anti-CCL2 neutralizing antibody (n = 3 to 
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5 per group) or (E) pre-treated i.v. with clodronate- or PBS-liposomes 24 hours before i.v. heat killed S. 
pneumoniae (107 CFU) for 6 hours (n = 6 to 8 per group). * p < 0.05 vs. WT, # p < 0.05 vs. 0 hour. 
 
3.10 Transcriptional remodeling coincides with liver injury in hepRelAΔ/Δ mice 
 To comprehensively evaluate RelA-dependent gene networks associated with 
liver injury during infection, we performed genome-wide expression analyses on liver 
RNA collected from WT and hepRelAΔ/Δ mice 0, 6, and 24 hours after i.v. S. 
pneumoniae. Bacteremia had a substantial effect on the liver transcriptome, and this 
response was remarkably exaggerated in RelA-deficient livers (Figure 13A-B). Indeed, 
by 24 hours, thousands of bacteremia-induced gene changes (FDR q < 0.05) were 
restricted to hepRelAΔ/Δ mice. Principal component analysis illustrated marked 
divergence in overall gene expression patterns amongst the experimental groups due to 
infection and/or genotype (Figure 13C). Most notably, the 24 hour WT samples closely 
resemble samples from uninfected mice, whereas the 24 hour hepRelAΔ/Δ samples 
comprise a highly distinct cluster. This analysis suggests that during the course of 
infection, the transcriptional landscape of WT livers returns to homeostasis, whereas that 
of hepRelAΔ/Δ livers has a divergent fate.  
 In order to begin dissecting gene programs associated with hepatotoxicity in 
hepRelAΔ/Δ mice, we used Ingenuity Pathway Analysis to align our data with curated data 
sets, including toxicological functions, potential upstream regulators, and biological 
functions (Table 7). Based on data acquired from differentially expressed genes (WT vs. 
hepRelAΔ/Δ; FDR q < 0.05; changes  2-fold), we unsurprisingly found that the top 5 
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toxicological functions all involved liver injury, whereas biological functions included 
several events both up- and downstream of immunotoxicity, such as immune cell 
trafficking and cell death. Top upstream regulators are led by TNF, which is highly 
consistent with our neutralization studies (Figures 7-8, 10-11); further, additional 
candidates were revealed which may also have important roles in liver homeostasis. 
Lastly, the most up- and downregulated genes include transcripts related to cell 
death/inflammatory injury (e.g. Cidec and Mmp12) (Cursio, Mari et al. 2002, Xu, Cai et 
al. 2015) and typical liver functions such as metabolism/acute phase proteins (e.g. 
Cyp8b1 and Saa3) (Zhang and Chiang 2001, Gruys, Toussaint et al. 2005) (Table 8). 
Together, these data reveal the scope of biological changes resulting from RelA 
deficiency, reinforce TNFα as a source of hepatotoxicity, and highlight additional factors 
that are likely involved with liver failure during infection.  
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Figure 13. The transcriptional response to bacteremia is remodeled in RelA-
deficient livers. 
WT and hepRelAΔ/Δ mice were challenged with i.v. S. pneumoniae (106) and microarray analysis was 
performed on liver RNA. (A) Venn diagrams illustrate the number of significantly altered genes due to 
bacteremia. False discovery rate (FDR) q < 0.05 after expression filtering. (B) Heatmap of genes from a 
two-way ANOVA (time point and genotype interaction, FDR q < 0.05), arbitrarily broken up into clusters 
of similar patterns of differential expression. Columns correspond to samples and rows correspond to a 
single gene. Red, white, and blue assigned genes indicate z-score-normalized expression z ≤ -2, 0, and ≥ 2, 
respectively. (C) Principal Component Analysis was performed to compare the overall variance amongst 
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experimental groups (WT or hepRelAΔ/Δ at 0, 6, or 24 hours post i.v. S. pneumoniae) across all detected 
transcripts. 
 
Top Predicted Upstream Regulators 
Regulator p-Value 
TNF 8.92E-50 
IL1B 5.40E-37 
IFNG 5.77E-34 
ACOX1 1.35E-30 
TGFB1 2.17E-29 
Top Toxicology Functions 
Category p-Value Gene No. 
Liver Steatosis 1.93E-16 - 2.53E-01 53 
Liver Inflammation / 
Hepatitis 2.71E-16 - 3.78E-01 56 
Liver Damage 5.94E-15 - 3.78E-01 51 
Liver Necrosis / Cell Death 3.28E-13 - 7.04E-02 41 
Liver Proliferation 1.84E-12 - 1.04E-01 35 
Top Disease & Biological Functions 
Category p-Value Gene No. 
Cellular Movement 9.27E-35 - 1.06E-07 269 
Immune Cell Trafficking 3.01E-34 - 1.06E-07 177 
Hematological System 
Development and Function 7.11E-29 - 1.06E-07 270 
Organismal Development 1.95E-28 - 7.35E-08 298 
Cell Death and Survival 5.52E-27 - 1.04E-07 331 
Table 7. Top predicted upstream regulators and functions of hepRelAΔ/Δ-specific 
gene changes. 
Candidate upstream regulators, toxicology, and biological functions identified by Ingenuity Pathway 
Analysis of genes significantly (FDR q < 0.05, Fold change ≥ 2) changed in hepRelAΔ/Δ 24 hours post i.v. 
S. pneumoniae as compared hepRelAΔ/Δ at 0 hours. 
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Top Upregulated Genes 
Symbol Name FDR q Fold Change 
Ly6d Lymphocyte antigen 6 complex, locus D 1.20E-05 ↑ 37.009 
Cidec Cell death-inducing DFFA-like effector c 4.11E-05 ↑ 30.656 
Mmp12 Matrix metallopeptidase 12 2.36E-06 ↑ 30.397 
A130040M12Rik RIKEN cDNA A130040M12 gene 4.64E-06 ↑ 19.591 
Tnfrsf12a Tumor necrosis factor receptor superfamily, member 12a 3.87E-06 ↑ 16.412 
Fam83a Family with sequence similarity 83, member A 1.21E-06 ↑ 13.131 
Slc25a30 Solute carrier family 25, member 30 7.33E-05 ↑ 12.393 
Nrg1 Neuregulin 1 1.76E-05 ↑ 11.336 
Il1rn Interleukin 1 receptor antagonist 8.71E-05 ↑ 10.632 
Egr1 Early growth response 1 7.18E-05 ↑ 10.334 
Top Downregulated Genes 
Symbol Name FDR q Fold Change 
Hsd3b5 
Hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and steroid 
delta-isomerase 5 
4.01E-02 ↓ -27.694 
Upp2 Uridine phosphorylase 2 1.12E-04 ↓ -19.709 
Keg1 Kidney expressed gene 1 4.92E-04 ↓ -11.621 
Saa3 Serum amyloid A 3 3.47E-04 ↓ -11.559 
Cyp8b1 Cytochrome P450, family 8, subfamily b, polypeptide 1 2.04E-04 ↓ -9.852 
Hamp2 Hepcidin antimicrobial peptide 2 1.44E-02 ↓ -9.681 
Abca8a ATP-binding cassette, sub-family A (ABC1), member 8a 2.04E-04 ↓ -8.420 
Cyp3a25 Cytochrome P450, family 3, subfamily a, polypeptide 25 7.99E-05 ↓ -8.152 
C730036E19Rik RIKEN cDNA C730036E19 gene 5.07E-05 ↓ -8.041 
Ppm1k Protein phosphatase 1K (PP2C domain containing) 2.16E-05 ↓ -7.989 
Table 8. Top 10 induced and reduced genes between WT and hepRelAΔ/Δ livers 
during bacteremia. 
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Transcriptional profiling was performed on whole liver RNA 24 hours post i.v. S. pneumoniae. Fold change 
of differentially expressed genes (WT vs. hepRelAΔ/Δ, FDR q < 0.05) were ranked. The top 10 most 
upregulated and downregulated genes are shown.  
 
 
.
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CHAPTER FOUR: HEPATIC STAT3 ACTIVATION MODULATES THE 
PULMONARY MICROENVIRONMENT DURING ENDOTOXEMIA 
 
Rationale 
 Sepsis is a syndrome defined by life-threatening organ dysfunction caused by a 
dysregulated host response to infection, and is a leading cause of mortality amongst 
critically ill patients (Walkey, Lagu et al. 2015, Singer 2016). Sepsis commonly arises 
from pneumonia (Mayr, Yende et al. 2014); however, non-pulmonary sepsis increases the 
susceptibility of patients to subsequent bacterial pneumonia (Alberti, Brun-Buisson et al. 
2002). A significant proportion of septic patients exhibit sepsis-induced 
immunosuppression or immune dysfunction, leading to complications of secondary 
infections and delayed recovery (Hotchkiss, Monneret et al. 2013). However, it is unclear 
how a pre-existing immune response to sepsis modulates responses to lung infections.  
 The hepatic acute phase response (APR) to infection and injury robustly modifies 
the liver transcriptome, altering gene programs including but not limited to those 
encoding acute phase proteins (APPs) (Gabay and Kushner 1999, Quinton, Blahna et al. 
2012). While APPs have long been appreciated as biomarkers for disease severity, their 
regulation and physiological significance in vivo are poorly understood (Gabay and 
Kushner 1999). It has been previously shown that transcription factors STAT3 and NF-
κB RelA (p65) are together required for activation of hepatic APR during pneumonia 
(Quinton, Jones et al. 2009, Quinton, Blahna et al. 2012, Hilliard, Allen et al. 2015). 
Hepatic STAT3 activation, in particular, has been shown to be important for limiting 
pneumonia susceptibility during endotoxemia (Hilliard, Allen et al. 2015).  
  
73
 Nutritional immunity is a process by which a host sequesters minerals during 
infections (Hood and Skaar 2012). Bacteria require iron among other transition metals for 
survival and modulation of iron availability is essential in hosts to prevent bacterial 
outgrowth and pathogenesis (Ratledge and Dover 2000). Defects in iron-regulating 
proteins in mouse models have been shown to worsen pneumonia and sepsis outcomes 
(Bachman, Lenio et al. 2012, Zeng, Chen et al. 2015), and patients with hemochromatosis 
are highly susceptible to infections (Khan, Fisher et al. 2007). While iron-regulating 
proteins can be produced in various tissues, the hepatic APR includes gene products, such 
as hepcidin, that are known to modulate iron availability (Johnson and Wessling-Resnick 
2012). However, neither the regulation nor the importance of liver-derived iron handling 
is understood in the context of pneumonia susceptibility. Therefore, we hypothesize that 
hepatic STAT3 activation is required for the amplification of iron-regulating factors 
during sepsis, and that this response is linked to reduced pneumonia susceptibility and 
mortality.  
 
Results 
4.1 Iron status is linked to liver activation during endotoxemia and sepsis 
 Prior studies from our laboratory in mice lacking STAT3 in hepatocytes 
demonstrated that STAT3-dependent gene expression during an endotoxemia is essential 
for limiting severity of subsequent pneumonia challenges (Hilliard, Allen et al. 2015). In 
these studies, hepSTAT3Δ/Δ mice exhibited increased mortality, and higher bacterial loads 
in the blood and lungs during pneumonia (Hilliard, Allen et al. 2015). However, 
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differences in inflammatory cytokines, pulmonary edema, and pulmonary cellularity were 
not observed between WT and hepSTAT3Δ/Δ mice (Hilliard, Allen et al. 2015), 
suggesting impairment of other mechanisms distinct from liver-dependent acute 
inflammation in mutant mice. Interestingly, cell- and bacteria-free BALF from 
hepSTAT3Δ/Δ mice was supportive of bacterial growth ex vivo (Hilliard, Allen et al. 
2015), suggesting the presence of humoral components derived from liver STAT3-
dependent changes confers pulmonary protection.   
 Because iron metabolism is an essential feature of bacterial growth and host 
defense during infections (Hood and Skaar 2012), we performed a study to examine the 
influence of STAT3 on liver mRNA induction of several iron-regulating genes during 
endotoxemia and subsequent E. coli pneumonia challenge. We focused on several 
representative iron regulating genes (hepcidin, hemopexin, haptoglobin, lipocalin, and 
transferrin receptor 2) which alter free iron availability by modulating absorption, release 
and transport of iron (Hood and Skaar 2012). In WT mice, endotoxemia induced 
transcription of all five genes, which were sustained 6 and 24 hours following the 
pneumonia challenge (Figure 14). In comparison, induction of these transcripts in 
hepSTAT3Δ/Δ mice remained at baseline (Figure 14). These findings were consistent in 
mice challenged in a cecal ligation and puncture (CLP) model, in which hepSTAT3Δ/Δ 
mice had significantly reduced induction of the select iron-regulating genes as compared 
to WT mice (Figure 15).  
 However, to further understand whether iron status in the lungs is dependent on 
liver STAT3 activation, we collected BALF from mice treated with LPS and measured 
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concentrations of iron by mass spectrometry. While the sample size is limited, the results 
trended towards increased iron in BALF of hepSTAT3Δ/Δ mice (Figure 16). Together, 
these results suggest iron-regulating proteins as an important intermediate between liver 
STAT3 activation and pulmonary defense during sepsis. 
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Figure 14. STAT3 is required for the expression of iron-handling factors during 
endotoxemia followed by pneumonia. 
WT and hepSTAT3Δ/Δ mice were challenged with i.p. LPS (5 mg/kg) or vehicle (saline) for 18 hours 
followed by i.t. of 106 CFU E. coli. Liver tissue was harvested at the indicated times after i.t. E. coli, and 
mRNA induction of representative iron-regulating factors was quantified by qRT-PCR. * p < 0.05 vs. WT; 
n = 3 to 6 per group. 
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Figure 15. STAT3 is required for the expression of iron-handling factors during 
polymicrobial sepsis. 
WT and hepSTAT3Δ/Δ mice underwent cecal ligation and puncture (CLP) or sham procedures. Mice were 
sacrificed 24 hours after surgery, and liver mRNA induction was determined for representative iron-
regulating factors using qRT-PCR. * p < 0.05 vs WT; n = 4 to 5 per group. 
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Figure 16. Alveolar iron content may be linked to hepatic STAT3 activity. 
WT and hepSTAT3Δ/Δ mice were challenged with i.p. LPS (5 mg/kg) or vehicle (saline) for 18 hours 
followed by i.t. of 106 CFU E. coli. BALF was collected 24 hours after i.t. E. coli for the assessment of free 
iron concentrations by mass spectrometry. Individual points represent a single sample.  
 
4.2 Sepsis-induced liver activation remodels lung transcription 
 While we hypothesize that iron-regulating APPs are an intermediate between liver 
STAT3 activation and pulmonary defense, we only investigated the induction of a select 
panel of iron-regulating genes. It is possible that other iron-handling APPs or other liver-
derived components can directly and indirectly influence the lung environment. For 
example, macrophage ROS production was decreased in hepSTAT3Δ/Δ mice after an 
endotoxemia challenge (Hilliard, Allen et al. 2015). In order to assess transcriptional 
changes due to STAT3-dependent liver activation, we performed RNA sequencing on 
whole lung tissue in WT and hepSTAT3Δ/Δ mice challenged with endotoxin and E. coli 
pneumonia (Figure 17). Due to substantial mortality in hepSTAT3Δ/Δ mice after 5 mg/kg 
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LPS challenge, the dose used in our prior study (Hilliard, Allen et al. 2015), the LPS dose 
was lowered to 1 mg/kg for these studies in order to ensure 100% survival.  
 To compare the influence of endotoxin on lung transcription, WT mice treated 
with vehicle were compared to WT mice treated with LPS. To compare the influence of 
pneumonia, mice challenged with LPS alone were compared to mice challenged with 
LPS followed by pneumonia. And, to compare the effect of liver STAT3 activation, both 
WT and hepSTAT3Δ/Δ mice were included in the LPS alone group and the LPS and 
pneumonia group. The effect of endotoxemia (WT vehicle vs. WT LPS; Figure 18A) 
yielded 7,791 significant gene changes in the lungs. While 1,859 significant (FDR q < 
0.05) gene changes were observed between genotypes during endotoxemia (WT vs. 
hepSTAT3Δ/Δ LPS; Figure 18B), there were no significant gene differences between 
genotypes after LPS and pneumonia (WT vs. hepSTAT3Δ/Δ LPS + E. coli; Figure 18C). 
Several upregulated (i.e. GCSF, GMCSF), unchanged (CXCL10, LIFR), and 
downregulated (WNT3a, SOX17) genes in hepSTAT3Δ/Δ following endotoxemia were 
validated by qRT-PCR (Figure 19). These data suggests that bacteria are encountering 
different lung environments influenced by liver STAT3 activation. Further analysis of 
differences in transcription due to endotoxemia or genotype may reveal potential liver-
dependent signals that confer pulmonary protection.  
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Figure 17. Groups for RNA-sequencing of whole lung tissues. 
WT and hepSTAT3Δ/Δ mice were challenged with i.p. LPS (1 mg/kg) or vehicle (saline) for 18 hours 
followed by i.t. of 106 CFU E. coli. Mice were sacrificed 0 hours after i.p. vehicle, 18 hours post i.p. LPS, 
or 24 hours post i.t. E. coli. RNA from left lung lobes were isolated from the indicated groups for RNA 
sequencing analysis and comparison. 
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Figure 18. The lung transcriptome is changed due to pre-existing STAT3-dependent 
liver activation. 
WT and hepSTAT3Δ/Δ mice were challenged with i.p. LPS or vehicle, and followed by i.t. E. coli (106) and 
RNA-sequencing analysis was performed on lung RNA. MA-plots illustrate the 18,000 differential genes 
according to log2 fold change and the mean of normalized counts between (A) WT vehicle vs. WT LPS, 
(B) WT LPS vs. hepSTAT3Δ/Δ, (C) WT LPS + E. coli vs. hepSTAT3Δ/Δ LPS + E. coli groups. Points 
colored red represent significantly altered genes (FDR q < 0.05) and points colored gray represent non-
significantly altered genes.  
 
  
83
 
Figure 19. Validation of select RNA sequencing findings by qRT-PCR. 
WT and hepSTAT3Δ/Δ mice were challenged with i.p. LPS (1 mg/kg) for 18 hours. Liver tissue was 
harvested and mRNA induction of representative significantly altered genes by RNA-seq (FDR q < 0.05) 
was quantified by qRT-PCR. * p < 0.05 vs. WT; n = 6 to 7 per group. 
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4.3 Liver STAT3 alters milieu of cytokines and chemokines in lungs after endotoxemia 
 To further confirm the results of our RNA sequencing analysis, we measured 
protein concentrations of several candidate genes changed between WT and 
hepSTAT3Δ/Δ mice challenged with endotoxin. Genes were selected based on association 
with pulmonary defense during pneumonia (Table 9). For example, several selected 
genes include cytokines and chemokines that are important recruitment of leukocytes, 
leukocyte activity, and lung remodeling (Wiersinga, Kager et al. 2010, van der Windt, 
Hoogendijk et al. 2011, Debruin, Hughes et al. 2014, Quinton, Walkey et al. 2018). GM-
CSF protein concentration in whole lung homogenates (Figure 20A) was reflective of 
both RNA-sequencing and qRT-PCR validation results. Additionally, some targets that 
were significantly increased in lung homogenates of hepSTAT3Δ/Δ mice were also 
represented in plasma (Figure 20B), suggestive of protein or cellular extravasation into 
the lungs after endotoxemia. While increases in chemokines in the lungs of mutant mice 
is suggestive of leukocyte recruitment and inflammation, the lung architecture and 
cellularity, as analyzed by histology, was unaffected between WT and hepSTAT3Δ/Δ 
mice. How these increases in cytokines during endotoxemia alter lung environment or 
contributes to susceptibility to pneumonia is still unclear.  
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Symbol Name FDR Fold Change 
Ccl19 C-C motif chemokine ligand 19 0.00977 ↑ 1.151 
Cxcl1 C-X-C motif chemokine 11 3.78 E-05 ↑ 1.416 
Csf3 Granulocyte-colony stimulator factor (G-CSF) 2.05 E-10 ↑ 3.413 
Cxcl2 C-X-C motif chemokine 2 1.9E-11 ↑ 1.403 
Il1a Interleukin 1 alpha 0.000137 ↑ 1.113 
Csf2 Granulocyte-macrophage colony-stimulating factor (GM-CSF) 3.90E-22 ↑ 2.533 
Il10 Interleukin 10 0.004724 ↑ 1.002 
Plaur Urokinase receptor (uPAR) 5.08E-05 ↑ 0.554 
Ccl2 C-C motif chemokine ligand 2 0.331637 ↑ 0.496 
Il6 Interleukin 6 0.413948 ↑ 1.168 
Spp1 Osteopontin 0.010267 ↓ -0.534 
Cd34 Podocalyxin 0.451132 ↓ -0.113 
Table 9. Candidate genes changed between WT and hepSTAT3Δ/Δ lungs during 
endotoxemia. 
RNA-sequencing analysis was performed on lung RNA of WT and hepSTAT3Δ/Δ mice challenged with 
LPS (1 mg/kg) for 18 hours. Genes were selected based on the ability to measure of equivalent proteins by 
commercially available multiplex bead array.  
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Figure 20. Lung and plasma cytokine changes are associated with lung 
transcriptional changes during endotoxemia. 
Plasma from hepSTAT3Δ/Δ or WT mice 18 hours after i.p. LPS (1 mg/kg) were measured for concentrations 
of the indicated cytokines and chemokines by multiplex bead array * p < 0.05 vs. WT; n = 7 to 11 per 
group.  
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Figure 21. Lung architecture and cellularity is not altered after endotoxemia in 
hepSTAT3Δ/Δ mice. 
Lungs were collected 24 hours after i.p. LPS (1 mg/kg) for 18 hours, and processed for histological analysis 
by hematoxylin and eosin (H&E) staining. Representative images are shown for each genotype. Scale bar: 
75 μm. 
 
 
.
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CHAPTER FIVE: DISCUSSION 
 
Role of RelA-dependent APR activation in hepatoprotection 
 The results of this study are the first to indicate a requirement for RelA-driven 
inducible hepatoprotection during pneumonia and bacteremia. Across several pneumonia 
and sepsis models, the absence of hepatocyte RelA resulted in TNFα-driven 
hepatotoxicity associated with exaggerated extrinsic apoptosis. These changes were also 
associated with substantial remodeling of the hepatic transcriptome, likely reflecting 
processes that underlie both cause and consequence of liver pathology and laying the 
foundation for future investigations. Although we were unable to identify a prominent 
cell type required for infection-induced liver failure in mutant mice, our results support a 
role for hepatocyte RelA in countering hepatotoxicity driven by NKT cell activity. As the 
liver represents an important reservoir of NKT cells (Liaskou, Wilson et al. 2012), this 
finding likely has important implications for our understanding of liver toxicity, including 
but not limited to that triggered by infection.  
 The liver represents the first line of defense during sepsis, but it is also a common 
target of dysregulation during infections (Minemura, Tajiri et al. 2014). The mean 
incidence of liver dysfunction is nearly 40% in patients with sepsis, and development of 
liver dysfunction is associated with high mortality rates (Wang, Yin et al. 2014, Yan, Li 
et al. 2014, Nesseler, Launey et al. 2016). Studies have shown that processes leading to 
liver dysfunction include aggressive systemic inflammatory reactions to bacterial toxins 
(Csak, Ganz et al. 2011), immune cells and mediators (Hutchins, Wang et al. 2013, 
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Wang, Yin et al. 2014), and changes in organ perfusion (Canabal and Kramer 2008). As 
the leading cause of sepsis (Mayr, Yende et al. 2014), pneumonia represents a critical 
threat to the liver. Independently of sepsis per se, pneumonia is associated with liver 
failure, and even modest changes in liver function tests may be predictive of pneumonia 
outcome (Jinks and Kelly 2004, Xu, Ying et al. 2018). However, mechanisms of 
hepatoprotection in the face of these damaging stimuli are not well understood. We posit 
that hepatoprotective measures of the APR represent an important means through which 
the liver limits the systemic consequences of infection, likely compartmentalizing 
inflammatory responses to locally infected tissues such as the lungs.   
 The liver has many functions, including its critical impact on both metabolic and 
immunological homeostasis (Strnad, Tacke et al. 2017). The APR, most quintessentially 
defined by the release of classic acute phase proteins such as CRP (Gabay and Kushner 
1999), is one such function; yet, its net physiological significance remains speculative. 
Here we propose the induction of tissue resilience pathways as a critical and active liver 
function during pneumonia and bacteremia, extending the definition of the APR to 
include cell and organ self-preservation. Our previous investigation demonstrated that 
ablation of the hepatic APR (via combined deletion of RelA and STAT3) compromises 
immunity, survival, and liver integrity during pneumonia (Hilliard, Allen et al. 2015). 
However, the experimental circumstances of that study, which were limited to a single 
challenge (Gram-negative pneumonia), were such that the distinct roles of STAT3 and 
RelA could not be distinguished. Here we show that while both transcription factors are 
ultimately critical for pneumonia outcome (Quinton, Jones et al. 2009, Quinton, Blahna et 
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al. 2012, Hilliard, Allen et al. 2015), hepatoprotection is exclusively attributable to RelA. 
Furthermore, the importance of RelA-driven liver protection extends beyond pneumonia, 
possibly limiting the degree to which systemic infection (with or without pneumonia) 
progresses to organ injury and sepsis.  
  Unlike RelA, deletion of STAT3 alone did not affect liver injury or mortality in 
our E. coli pneumonia model, contrasting previous reports of STAT3-dependent 
hepatoprotection. However, many of these studies are in non-infectious settings such as 
liver tumorigenesis (Wang, Lafdil et al. 2011), Fas-driven injury (Haga, Terui et al. 
2003), and chemical toxicity (Feng, Wang et al. 2014, Hafez, Al-Harbi et al. 2015). On 
the other hand, a connection between RelA and liver protection has been previously 
established. RelA knockout mice exhibit TNFα-dependent liver failure and death during 
gestation (Beg, Sha et al. 1995). Additional studies have revealed RelA as a driver of 
anti-apoptotic and cell survival genes (D'Souza, Edelstein et al. 2004), as well as its 
potential role in subverting TNF-induced immunotoxicity in both embryonic 
(Rosenfeld, Prichard et al. 2000) and adult livers (Geisler, Algul et al. 2007). Deletion of 
IKKβ, a different component of the NF-κB pathway, also resulted in liver injury and 
apoptosis following ConA or LPS stimulation, and ischemia-reperfusion injury (Maeda, 
Chang et al. 2003, Luedde, Assmus et al. 2005). Remarkably little is currently understood 
regarding RelA-driven hepatocyte protection during infection. Clinically, RelA 
expression has been associated with a lower degree of apoptosis and cirrhosis in livers of 
patients with hepatitis C (Boya, Larrea et al. 2001). Moreover, decreased expression of 
RelA was noted in pregnant women infected with hepatitis E, and liver RelA mRNA 
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levels were inversely associated with severe liver damage and mortality (Prusty, Hedau et 
al. 2007). Our current study extends the hepatoprotective and anti-apoptotic roles of 
hepatocyte RelA to include local and systemic bacterial infections (i.e. pneumonia and 
bacteremia), as well as non-infectious stimuli such as GalCer and heat-killed bacteria.  
 While the molecular mechanisms of RelA-dependent liver resilience are only 
beginning to be understood, our results suggest that these events counteract cell death 
driven by exaggerated apoptosis. Livers of hepRelAΔ/Δ mice contained higher levels of 
activated caspase-3 and -8 in several models tested. Caspase-8 cleavage is consistent with 
extrinsic apoptosis, typically driven by TNFα and related ligands through FADD (Eguchi, 
Wree et al. 2014). Not only was TNFα the top candidate upstream regulator of gene 
expression changes in hepRelAΔ/Δ livers after i.v. S. pneumoniae (Table 7), but, 
neutralization of this ligand reversed both liver injury and apoptosis. The necroptosis 
inhibitor Nec-1s, however, had no effect on liver injury in hepRelAΔ/Δ mice. Necroptosis 
has been associated with liver injury in certain settings (Cho, Challa et al. 2009, Jouan-
Lanhouet, Arshad et al. 2012), and both apoptosis and necroptosis have been attributed to 
embryonic lethality in RelA knockout mice (Xu, Wu et al. 2018). Based on our results, 
we speculate that if necroptosis is, in fact, related to liver injury during infection, such 
pathology was overwhelmed by TNFα-driven apoptosis. Thus, we speculate that our 
observed phenotype may be largely due to secondary necrosis (Silva 2010). 
Paradoxically, TNFα-induced NF-κB is required for initiating the hepatic APR (Quinton, 
Jones et al. 2009), which involves NF-B-dependent protection from TNF itself. We 
posit that in the absence of RelA, TNFα signaling favors the cell death pathway, whilst 
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protective NF-κB-driven anti-apoptotic signals, such as cFLIP (Kondylis, Kumari et al. 
2017), remain dormant. Furthermore, we observed a positive association between liver 
TNFα expression and injury in hepRelAΔ/Δ mice, suggesting that TNFα is both up- and 
downstream of hepatotoxicity without the protection normally afforded by RelA.  
 Transcriptional profiling revealed that the consequences of liver RelA deletion are 
vast, including but not limited to changes in gene networks related to cell-survival (Table 
8). A limitation to this study, and this outcome in particular, is the difficulty in 
distinguishing cause from effect. Major transcriptional remodeling was not observed until 
24 hours of bacteremia, a time by which liver injury was severe (Figure 13). This 
phenotype is almost certainly attributable to some of the identified gene changes, but 
others are likely altered in response to the injury itself.  Similarly, other gene changes 
may or may not reflect differences in liver cellularity, both up- and downstream of injury. 
Indeed, immune cell trafficking genes are highly represented amongst those differentially 
expressed based on our bioinformatic analyses (Table 8). Ultimately, these results 
provide important avenues for future investigation. 
 While the results unequivocally reveal TNF as a prominent cause of 
immunopathology in the absence of hepatocyte RelA, the cellular sources of this cytokine 
remain unknown under the conditions studied. We focused on populations of leukocytes 
that have been implicated in liver injury and aging (as suggested by Figure 5) (Mehal, 
Azzaroli et al. 2001, Hilmer, Cogger et al. 2007). NKT and Kupffer cells, in particular, 
are sufficient to promote liver injury through production of cytokines and other 
inflammatory mediators (Hu, Venet et al. 2009, Hutchins, Wang et al. 2013). Our results 
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utilizing αGalCer to specifically activate NKT cells demonstrate that these cells are 
sufficient to drive TNF-dependent hepatotoxicity in the absence of hepatocyte RelA, 
implicating them as a source of this cytokine. However, blocking NKT cell activity was 
inconsequential with regards to liver injury, suggesting alternative TNF sources. 
Notably, inactivation of NKT cells during a live E. coli infection markedly impaired 
defense, which is reflective of other infection models (Brigl, Tatituri et al. 2011) and 
consistent with the notion that NKT cells are essential in this setting. Similarly, we did 
not observe changes in liver injury in hepRelAΔ/Δ mice after depletion of Kupffer cells 
(using clodronate liposomes), nor was there an effect of blocking monocyte recruitment 
(using a CCL2-neutralizing Ab). We also isolated liver NK cells, NKT cells, Kupffer 
cells, and recruited monocytes following bacteremia in an effort to identify their 
respective capacities to synthesize TNF. However, we did not observe significant TNF 
mRNA induction in any case, suggesting other potential sources of this cytokine. One 
possible explanation for our results is that our leukocyte blockade/depletion strategies 
were insufficient. However, we find this unlikely given the routine nature of these 
procedures and/or other coinciding outcomes (e.g. increased bacterial burdens following 
anti-CD1d (Figure 11A)). Perhaps the more likely alternative is that other cell types such 
as lymphocytes, endothelial cells, hepatic stellate cells, neutrophils, and/or injured 
hepatocytes themselves are more prominently connected to hepatotoxicity (Strnad, Tacke 
et al. 2017). These include extra-hepatic cells that may serve as distant sources of 
injurious mediators.  
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 Our present study is the first to investigate the direct role of hepatocyte RelA in 
response to pneumonia and bacteremia. Based on these findings, RelA-dependent gene 
programs are a critical component of the hepatic APR, fortifying liver homeostasis and 
survival by shielding against TNF-dependent immunotoxicity. Future studies designed 
to reveal signaling pathways mechanistically linked to RelA-dependent protection may 
help identify or treat individuals with or at risk for pneumonia and sepsis. 
 
Role of STAT3-dependent APR activation on lung defense 
 The results of this study implicate a mechanism by which STAT3-dependent 
activation of the hepatic acute phase response promotes iron withdrawal and lung 
defenses to counter sepsis-induced pneumonia. We observed the induction of several 
iron-regulating genes in mice following a two-hit model of endotoxemia followed by E. 
coli pneumonia.  Similar results were also observed following a cecal ligation and 
puncture challenge. However, induction was impaired in mice lacking hepatocyte 
STAT3. We also discovered that sepsis-induced liver activation remodels the lung 
transcriptome, providing potential signals and mechanisms of liver-dependent protection 
for future studies.  
 Previous studies from our group have demonstrated that in the absence of 
hepatocyte STAT3, mice exhibited heightened susceptibility to pneumonia during 
endotoxemia, as evidenced by increased bacterial burdens and mortality (Hilliard, Allen 
et al. 2015). While it is established that sepsis has immunosuppressive effects that 
promote pneumonia  susceptibility (Benjamim, Hogaboam et al. 2003, Jung, Perrone et 
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al. 2012, Sundar and Sires 2013), very little is known about liver contributions to this 
process. Several studies support a role for hepatocyte STAT3 in activation of the liver 
APR during endotoxemia (Alonzi, Maritano et al. 2001, Delano, Thayer et al. 2011), 
including its importance for survival and cytokine regulation during CLP (Sakamori, 
Takehara et al. 2007, Sander, Sackett et al. 2010). Furthermore, our own prior study 
implicates STAT3-dependent acute phase responses in modulating the constituents of 
airspace lining fluid, providing humoral protection against bacterial outgrowth (Hilliard, 
Allen et al. 2015). However, the mechanisms directing lung immunity during sepsis is 
less clear. 
 While the direct influence of liver-derived iron regulatory factors has never been 
determined in the context of sepsis-induced pneumonia susceptibility, our studies show 
that hepatic STAT3 activation is essential for the induction of several iron-regulating 
proteins during endotoxemia and polymicrobial sepsis. Trends towards increased iron 
concentrations in the airspace lining fluid implicate a link between liver activation and 
changes in lung environment. Based on the above results, it is plausible that STAT3-
dependent liver activation dispatches iron handling proteins to the circulation and/or the 
pneumonic airspaces to limit systemic and local iron availability for bacteria. Similar 
results have shown IL-6 dependent induction of hepcidin from the liver was important for 
preventing bacteremia following respiratory K. pneumoniae challenge (Michels, Zhang et 
al. 2017).  
 Our current investigation is limited to only a select group of iron-handling APPs. 
To complement our initial studies focused on iron-handling factors, we performed RNA-
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sequencing to comprehensively evaluate the degree to which lungs are transcriptionally 
remodeled by endotoxemia in mice lacking hepatocyte STAT3. Surprisingly, the near 
2,000 significant gene changes in the lung due to STAT3-activation by LPS, were lost 
following the onset of pneumonia. We speculate that the combined effects of both 
endotoxemia and E. coli-induced pneumonia, which resulted in over 13,000 significant 
lung gene changes vs. unchallenged mice (data not shown), simply overwhelmed the 
biological capacity of the system to detect further changes due to liver genotype. 
Importantly, however, our data reveal that STAT3-dependent liver activity drastically 
alters the transcriptional landscape of the lungs during endotoxemia, and future 
investigations to determine how this renders lungs vulnerable to subsequent infections 
represent a high priority for our research program. Corresponding with lung 
transcriptional profiles, the systemic LPS challenge significantly altered several cytokines 
in both whole lung tissues and plasma, including GM-CSF, CXCL1, and CXCL2. 
However, in studies employing a similar experimental design, albeit with a higher dose of 
i.p. LPS (5 mg/kg vs. 1 mg/kg), we previously showed only modest changes in the BALF 
and plasma of few common cytokines (Hilliard, Allen et al. 2015). We speculate that this 
is mostly due to what can be significant effects of lowering LPS concentrations 
(Monguio-Tortajada, Franquesa et al. 2018), along with the identity of the examined 
specimen (BALF vs. lung tissue homogenate).  
 These early studies demonstrate liver STAT3-dependent iron sequestration and 
lung remodeling as potential means of improving protection against respiratory infections 
during sepsis. Ongoing studies will further determine the impact of liver STAT3 activity 
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on iron-regulating factors and pulmonary signals, and whether these responses are 
mechanistically linked to pneumonia susceptibility. 
 
Future Directions 
 Our studies reveal a direct and critical role of hepatocyte RelA during pneumonia 
and sepsis in countering TNFα-driven programmed cell death. Future studies are required 
to determine cells and signals both up- and downstream of liver injury in RelA-deficient 
mice. This information is important for dissecting the physiological pathways that 
normally serve to limit liver injury during infection.  For instance, additional experiments 
are needed to follow up on those above to determine the cellular requirements of liver 
injury in vulnerable (RelA-deficient) mice. Outside of those discussed, others include, but 
are not limited to NK cells (Tian, Chen et al. 2013), damaged liver sinusoidal endothelial 
cells (LSECs) (Ni, Li et al. 2017), dendritic cells (Dou, Ono et al. 2018), and neutrophils 
which accumulate in the liver during injury (Xu, Huang et al. 2014). 
 Interrogating the mechanisms of interaction between cells and hepatocytes 
leading to cell death is an important avenue of future studies. The sources of TNFα 
during these severe infections are still unknown. In the contexts of pneumonia and 
bacteremia, the sources of TNFα could be intra-hepatic, extra-hepatic, or both. 
Additionally, TNFα is only one of several known death receptor ligands, including 
TRAIL and FasL, which contribute to hepatocyte death (Tsutsui, Matsui et al. 1997, 
Ochi, Ohdan et al. 2004). Significant liver injury and serum transaminase levels 
following pneumonia and sepsis suggest injured hepatocytes as a potential and prominent 
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source of danger associated molecular patterns (DAMPs). DAMPs such as high-mobility 
group protein B1 (HMGB1) and mitrochondrial DNA (mtDNA) are implicated in sepsis 
severity and acute liver failure (Yang, Ochani et al. 2004, Evankovich, Cho et al. 2010, 
Zhang, Raoof et al. 2010). DAMPs may promote and sustain liver injury when protective 
mechanisms go awry.  
 Signals downstream of hepatocyte RelA required to counter programmed cell 
death or promoting homeostasis are also unclear. Analysis of differentially expressed 
genes from our microarray dataset may reveal anti-apoptotic or other protective pathways 
controlled by RelA. This will be complemented by a more targeted approach to 
interrogate whether select RelA-dependent factors are sufficient or necessary to prevent 
hepatotoxicity, 
 Our other studies implicate a mechanism by which STAT3-dependent liver 
activity promotes iron withdrawal and lung defenses to counter sepsis-induced 
pneumonia. However, the studies did not mechanistically link iron regulation, per se, to 
protection, nor did they reveal which of the numerous affected lung pathways are 
genuinely responsible for immunity and survival. Future studies should confirm changes 
in iron and iron-handling proteins, as well as the degree to which iron manipulation can 
recapitulate or prevent the observed phenotype of STAT3-deficient mice during 
endotoxemia.  
 The goal of the present studies was to better understand the integrated responses 
influencing susceptibility during pneumonia and sepsis. Improvement in our 
understanding of how changes in the hepatic acute phase response influence liver 
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homeostasis, sepsis susceptibility, and mortality during pneumonia and sepsis may reveal 
novel signaling pathways that can be targeted for clinical intervention in patients with or 
at risk for these conditions.
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